Variant_b37	Trait	Variant_type	Gene	VariationID	AlleleID	LastEvaluated	high_confidence_lab_2017_clinical_significance	Level	Notes	AMP-T2D-GENES	UKBB	Assessment_Notes	Additional_independent_assessment	Additional_independent_assessment_notes	Variant
16-56995902-CCA-C	High HDL	LOF	CETP	NA	NA	NA	NA	lof	pext = 1	NA	4	NA	NA	NA	chr16-56961990-CCA-C
16-56996010-G-A	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-56996920-A-G	High HDL	LOF	CETP	NA	NA	NA	NA	lof	no rescue sites available	NA	1	NA	NA	NA	chr16-56963008-A-G
16-56996921-G-A	High HDL	LOF	CETP	NA	NA	NA	NA	lof		2	NA	NA	NA	NA	NA
16-56996963-C-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-57003374-C-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof		NA	3	NA	NA	NA	chr16-56969462-C-T
16-57003521-A-G	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-57004961-C-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof		NA	2	NA	NA	NA	chr16-56971049-C-T
16-57005910-TC-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	partial exon conservation pext=1	NA	2	NA	NA	NA	chr16-56971998-TC-T
16-57005975-TA-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	partial exon conservation pext=1	NA	1	NA	NA	NA	chr16-56972063-TA-T
16-57007270-G-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof		3	NA	NA	NA	NA	NA
16-57007274-ACCTC-A	High HDL	LOF	CETP	NA	NA	NA	NA	lof		2	NA	NA	NA	NA	NA
16-57007306-C-CT	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-57007345-C-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	reads look good, sort of low pext 0.27	2	3	NA	NA	NA	chr16-56973433-C-T
16-57009011-A-G	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-57009034-TTCAACACCAA-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	pext=1	NA	4	NA	NA	NA	chr16-56975122-TTCAACACCAA-T
16-57009049-G-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	PHYLOCSF_WEAK, but entire gene has low conservation	3	NA	NA	NA	NA	NA
16-57012122-TC-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	PHYLOCSF_WEAK, but entire gene has low conservation	4	NA	NA	NA	NA	NA
16-57012144-TC-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	pext=1	NA	1	NA	NA	NA	chr16-56978232-TC-T
16-57015069-G-A	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-57015138-G-A	High HDL	LOF	CETP	NA	NA	NA	NA	lof		2	NA	NA	NA	NA	NA
16-57015555-TCAGGATTACAC-T	High HDL	LOF	CETP	NA	NA	NA	NA	lof	alamut predicts out of frame strong rescue  pext=1	NA	1	NA	NA	NA	chr16-56981643-TCAGGATTACAC-T
16-57015557-A-G	High HDL	LOF	CETP	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
16-57015570-A-AGC	High HDL	LOF	CETP	NA	NA	NA	NA	lof	no reads available  check for frame restore  pext=1	NA	1	NA	NA	NA	chr16-56981658-A-AGC
16-57015572-AC-A	High HDL	LOF	CETP	NA	NA	NA	NA	lof	pext=1 no read data	NA	1	NA	NA	NA	chr16-56981660-AC-A
16-57003855-G-GC	High HDL	LOF	CETP	NA	NA	NA	NA	likely_lof	Genotyping error	1	NA	NA	NA	NA	NA
16-57005232-G-C	High HDL	LOF	CETP	NA	NA	NA	NA	likely_lof	weak alt splice site 12 bp into exon  partial exon conservation  pext=1	NA	1	NA	NA	NA	chr16-56971320-G-C
16-57007282-CT-C	High HDL	LOF	CETP	NA	NA	NA	NA	likely_not_lof	low pext in exon	4	NA	NA	NA	NA	NA
16-57017318-C-T	High HDL	LOF	CETP	NA	NA	NA	NA	likely_not_lof		NA	3	NA	NA	NA	chr16-56983406-C-T
16-56996009-TGTAA-T	High HDL	LOF	CETP	NA	NA	NA	NA	not_lof	Essential splice site rescue, pext=1	6	5	NA	NA	NA	chr16-56962097-TGTAA-T
16-57003594-G-A	High HDL	LOF	CETP	NA	NA	NA	NA	not_lof	nagnag	NA	2	NA	NA	NA	chr16-56969682-G-A
16-57005295-T-C	High HDL	LOF	CETP	NA	NA	NA	NA	not_lof	Essential splice site rescue	1	NA	NA	NA	NA	NA
16-57016150-G-A	High HDL	LOF	CETP	NA	NA	NA	NA	not_lof	Essential splice site rescue, nagnag	3	4	NA	NA	NA	chr16-56982238-G-A
16-57016150-G-T	High HDL	LOF	CETP	NA	NA	NA	NA	not_lof	nagnag	NA	3	NA	NA	NA	chr16-56982238-G-T
2-21229160-C-T	High LDL	ClinVar	APOB	17890	32929	11-Jul-18	Pathogenic, Pathogenic, Pathogenic	pathogenic	Relatively high frequency, but hypercholesterolemia has reduced prevalence and other evidence is very convincing	7	28	NA	NA	NA	chr2-21006288-C-T
2-21229161-G-A	High LDL	ClinVar	APOB	40223	48709	3-Jul-18	Pathogenic, Pathogenic, Pathogenic	pathogenic	High frequency, likely due to fact that it can have recessive inheritence for low LDL	13	1	NA	NA	NA	chr2-21006289-G-A
2-21230565-G-A	High LDL	ClinVar	APOB	69508	80399	16-Oct-17	Likely pathogenic, Uncertain significance	vus	High Confidence Lab's conflicted, and reassessed because of high allele count,  reassessed as VUS	1	NA	NA	NA	NA	NA
19-11200236-G-A	High LDL	ClinVar	LDLR	237860	243266	30-Mar-17	NA	pathogenic		1	NA	NA	NA	NA	NA
19-11210962-G-A	High LDL	ClinVar	LDLR	3741	18780	14-Nov-17	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11213359-CG-C	High LDL	ClinVar	LDLR	251078	245421	14-Feb-18	Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11102683-CG-C
19-11213408-T-G	High LDL	ClinVar	LDLR	3685	18724	8-Jun-18	Pathogenic	pathogenic		2	2	NA	NA	NA	chr19-11102732-T-G
19-11213415-G-A	High LDL	ClinVar	LDLR	226312	228125	26-May-17	Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11102739-G-A
19-11213417-G-A	High LDL	ClinVar	LDLR	251105	245448	15-Jun-18	Pathogenic, Pathogenic	pathogenic		7	NA	NA	NA	NA	NA
19-11213445-C-G	High LDL	ClinVar	LDLR	161269	171198	6-May-17	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11213450-G-A	High LDL	ClinVar	LDLR	161266	171199	31-Oct-18	Pathogenic, Pathogenic, Pathogenic	pathogenic		1	5	NA	NA	NA	chr19-11102774-G-A
19-11213463-G-A	High LDL	ClinVar	LDLR	3736	18775	16-Jul-18	Pathogenic, Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11102787-G-A
19-11215918-C-CG	High LDL	ClinVar	LDLR	440560	434210	6-Feb-17	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11216011-C-A	High LDL	ClinVar	LDLR	226325	228138	5-Dec-17	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11216083-C-A	High LDL	ClinVar	LDLR	200918	198011	20-Mar-18	Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11105407-C-A
19-11216084-G-A	High LDL	ClinVar	LDLR	183136	181228	28-Jun-18	Pathogenic	pathogenic		2	3	NA	NA	NA	chr19-11105408-G-A
19-11216105-G-A	High LDL	ClinVar	LDLR	3726	18765	2-Jan-18	NA	pathogenic		2	NA	NA	NA	NA	NA
19-11216213-C-T	High LDL	ClinVar	LDLR	251335	245672	25-Apr-18	Pathogenic	pathogenic		2	NA	NA	NA	NA	NA
19-11216232-ATGG-A	High LDL	ClinVar	LDLR	226329	228142	25-Jun-18	Pathogenic, Pathogenic	pathogenic		1	2	NA	NA	NA	chr19-11105556-ATGG-A
19-11216244-A-G	High LDL	ClinVar	LDLR	183092	181233	3-Apr-17	Pathogenic	pathogenic		NA	3	NA	NA	NA	chr19-11105568-A-G
19-11216261-GAC-G	High LDL	ClinVar	LDLR	3731	18770	15-Jun-18	Pathogenic, Pathogenic	pathogenic		NA	2	NA	NA	NA	chr19-11105585-GAC-G
19-11216263-C-G	High LDL	ClinVar	LDLR	3690	18729	30-Jun-17	Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11105587-C-G
19-11216264-G-A	High LDL	ClinVar	LDLR	3691	18730	19-Jan-18	Pathogenic, Pathogenic	pathogenic		2	NA	NA	NA	NA	NA
19-11216264-G-C	High LDL	ClinVar	LDLR	251393	245730	15-Aug-17	Pathogenic	pathogenic		3	NA	NA	NA	NA	NA
19-11217344-T-A	High LDL	ClinVar	LDLR	161287	171201	17-May-18	Pathogenic, Pathogenic, Pathogenic	pathogenic		1	1	NA	NA	NA	chr19-11106668-T-A
19-11221435-C-T	High LDL	ClinVar	LDLR	226342	228156	8-May-18	Pathogenic, Pathogenic	pathogenic		1	2	NA	NA	NA	chr19-11110759-C-T
19-11221442-G-A	High LDL	ClinVar	LDLR	36450	45113	11-Apr-17	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11222232-G-A	High LDL	ClinVar	LDLR	251665	245988	5-Jun-18	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11223944-G-A	High LDL	ClinVar	LDLR	226349	228162	30-Mar-17	Pathogenic	pathogenic		2	1	NA	NA	NA	chr19-11113268-G-A
19-11223983-C-A	High LDL	ClinVar	LDLR	3746	18785	13-Apr-18	Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11223983-C-T	High LDL	ClinVar	LDLR	226351	228164	30-Mar-17	NA	pathogenic		2	1	NA	NA	NA	chr19-11113307-C-T
19-11224052-G-A	High LDL	ClinVar	LDLR	3694	18733	31-Oct-18	Pathogenic	pathogenic		1	1	NA	NA	NA	chr19-11113376-G-A
19-11224058-G-A	High LDL	ClinVar	LDLR	3695	18734	30-Mar-17	NA	pathogenic		1	NA	NA	NA	NA	NA
19-11224109-C-T	High LDL	ClinVar	LDLR	251798	246112	30-Mar-17	NA	pathogenic		1	NA	NA	NA	NA	NA
19-11224319-C-G	High LDL	ClinVar	LDLR	161270	171215	25-Mar-16	NA	pathogenic		1	NA	NA	NA	NA	NA
19-11224326-G-A	High LDL	ClinVar	LDLR	161285	171216	2-Jan-18	NA	pathogenic		3	1	NA	NA	NA	chr19-11113650-G-A
19-11227576-C-T	High LDL	ClinVar	LDLR	200921	198015	23-Jan-18	Pathogenic	pathogenic		13	NA	NA	NA	NA	NA
19-11227604-G-A	High LDL	ClinVar	LDLR	161271	171217	22-May-18	Pathogenic, Pathogenic, Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11227613-G-A	High LDL	ClinVar	LDLR	183126	181268	11-Apr-18	Pathogenic	pathogenic		5	NA	NA	NA	NA	NA
19-11230819-C-T	High LDL	ClinVar	LDLR	226379	228192	14-Jan-18	Pathogenic, Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11120143-C-T
19-11231057-T-C	High LDL	ClinVar	LDLR	252163	246458	16-Dec-16	NA	pathogenic	Insufficient evidence	4	NA	NA	NA	NA	NA
19-11231087-T-C	High LDL	ClinVar	LDLR	226384	228197	8-May-18	Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11120411-T-C
19-11231101-C-A	High LDL	ClinVar	LDLR	3699	18738	16-Sep-18	Pathogenic, Pathogenic	pathogenic		1	NA	NA	NA	NA	NA
19-11231112-C-T	High LDL	ClinVar	LDLR	3702	18741	31-Oct-18	Pathogenic	pathogenic		NA	5	NA	NA	NA	chr19-11120436-C-T
19-11231118-T-TC	High LDL	ClinVar	LDLR	68103	78994	29-Dec-17	Pathogenic, Pathogenic	pathogenic		NA	1	NA	NA	NA	chr19-11120442-T-TC
19-11233979-CT-C	High LDL	ClinVar	LDLR	226388	228201	11-May-17	Pathogenic, Pathogenic	pathogenic		2	NA	NA	NA	NA	NA
19-11240274-C-G	High LDL	ClinVar	LDLR	161265	171224	30-Mar-17	NA	pathogenic		2	NA	NA	NA	NA	NA
19-11211025-A-T	High LDL	ClinVar	LDLR	225097	226972	23-Oct-17	Pathogenic, Likely pathogenic	likely pathogenic		2	NA	NA	NA	NA	NA
19-11215919-G-A	High LDL	ClinVar	LDLR	237872	243268	8-Feb-18	Likely pathogenic	likely pathogenic	Insufficient evidence	2	3	NA	NA	NA	chr19-11105243-G-A
19-11217342-G-A	High LDL	ClinVar	LDLR	226334	228147	19-Sep-17	NA	likely pathogenic		1	NA	NA	NA	NA	NA
19-11218112-G-A	High LDL	ClinVar	LDLR	161268	171204	1-May-18	Likely pathogenic	likely pathogenic		5	NA	NA	NA	NA	NA
19-11218160-G-A	High LDL	ClinVar	LDLR	3692	18731	10-Apr-18	Likely pathogenic, Pathogenic	likely pathogenic		1	NA	NA	NA	NA	NA
19-11218162-C-G	High LDL	ClinVar	LDLR	226336	228149	2-Jan-18	NA	likely pathogenic		NA	1	NA	NA	NA	chr19-11107486-C-G
19-11221373-G-A	High LDL	ClinVar	LDLR	226344	228154	16-Dec-16	NA	likely pathogenic		3	NA	NA	NA	NA	NA
19-11222262-A-C	High LDL	ClinVar	LDLR	183108	181249	30-Mar-17	Likely pathogenic	likely pathogenic		NA	1	NA	NA	NA	chr19-11111586-A-C
19-11223968-C-G	High LDL	ClinVar	LDLR	161267	171211	11-May-18	Likely pathogenic	likely pathogenic		1	NA	NA	NA	NA	NA
19-11223989-G-A	High LDL	ClinVar	LDLR	36453	45116	23-Jan-18	Likely pathogenic	likely pathogenic		1	1	NA	NA	NA	chr19-11113313-G-A
19-11224005-C-T	High LDL	ClinVar	LDLR	161276	171212	23-Oct-17	Likely pathogenic	likely pathogenic		2	2	NA	NA	NA	chr19-11113329-C-T
19-11224266-G-T	High LDL	ClinVar	LDLR	183116	181258	4-May-18	Likely pathogenic	likely pathogenic		NA	3	NA	NA	NA	chr19-11113590-G-T
19-11224284-G-A	High LDL	ClinVar	LDLR	161277	171213	26-Apr-18	Likely pathogenic	likely pathogenic		1	NA	NA	NA	NA	NA
19-11224296-G-A	High LDL	ClinVar	LDLR	161284	171214	11-May-17	NA	likely pathogenic		NA	5	NA	NA	NA	chr19-11113620-G-A
19-11224354-C-T	High LDL	ClinVar	LDLR	251874	246188	30-Aug-17	Likely pathogenic	likely pathogenic		NA	1	NA	NA	NA	chr19-11113678-C-T
19-11224443-G-C	High LDL	ClinVar	LDLR	440652	434303	30-May-17	Likely pathogenic	likely pathogenic	High Confidence Lab	3	NA	NA	NA	NA	NA
19-11226817-G-A	High LDL	ClinVar	LDLR	251945	246250	31-Oct-18	NA	likely pathogenic	Might have used PM2_supporting, but would still be LP	NA	2	NA	NA	NA	chr19-11116141-G-A
19-11226874-A-G	High LDL	ClinVar	LDLR	224616	226401	24-Apr-18	Likely pathogenic	likely pathogenic	Insufficient evidence	2	1	NA	NA	NA	chr19-11116198-A-G
19-11227549-C-T	High LDL	ClinVar	LDLR	183123	181265	11-Dec-17	Likely pathogenic	likely pathogenic	High Confidence Lab	1	1	NA	NA	NA	chr19-11116873-C-T
19-11227550-G-A	High LDL	ClinVar	LDLR	251996	246297	3-Jul-18	Likely pathogenic	likely pathogenic		3	NA	NA	NA	NA	NA
19-11227612-C-T	High LDL	ClinVar	LDLR	161290	171218	24-Oct-17	Likely pathogenic	likely pathogenic		2	1	NA	NA	NA	chr19-11116936-C-T
19-11231095-T-A	High LDL	ClinVar	LDLR	252183	246478	16-Dec-16	NA	likely pathogenic		NA	1	NA	NA	NA	chr19-11120419-T-A
19-11231154-C-T	High LDL	ClinVar	LDLR	252219	246513	9-Oct-17	Likely pathogenic	likely pathogenic		5	NA	NA	NA	NA	NA
19-11210962-G-A	High LDL	LOF	LDLR	3741	18780	14-Nov-17	Pathogenic	lof		1	NA	NA	NA	NA	NA
19-11213445-C-G	High LDL	LOF	LDLR	161269	171198	6-May-17	Pathogenic	lof		1	NA	NA	NA	NA	NA
19-11215918-C-CG	High LDL	LOF	LDLR	440560	434210	6-Feb-17	Pathogenic	lof		1	NA	NA	NA	NA	NA
19-11216011-C-A	High LDL	LOF	LDLR	226325	228138	5-Dec-17	Pathogenic	lof		1	NA	NA	NA	NA	NA
19-11216077-G-A	High LDL	LOF	LDLR	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
19-11224109-C-T	High LDL	LOF	LDLR	251798	246112	30-Mar-17	NA	lof		1	NA	NA	NA	NA	NA
19-11224319-C-G	High LDL	LOF	LDLR	161270	171215	25-Mar-16	NA	lof		1	NA	NA	NA	NA	NA
19-11227607-GC-G	High LDL	LOF	LDLR	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
19-11231095-T-A	High LDL	LOF	LDLR	252183	246478	16-Dec-16	NA	lof		NA	1	NA	NA	NA	chr19-11120419-T-A
19-11231101-C-A	High LDL	LOF	LDLR	3699	18738	16-Sep-18	Pathogenic, Pathogenic	lof		1	NA	NA	NA	NA	NA
19-11231118-T-TC	High LDL	LOF	LDLR	68103	78994	29-Dec-17	Pathogenic, Pathogenic	lof		NA	1	NA	NA	NA	chr19-11120442-T-TC
19-11200236-G-A	High LDL	LOF	LDLR	237860	243266	30-Mar-17	NA	likely_lof	close to start but no obvious nearby in-frame ATG to rescue, weak exon conservation, low pext - 4 (I know that this first exon is not well expressed and conserved from doing curation. I also know that is is part of a pre-protein complex that is then removed for the mature protein to function. With that knowledge I would actually use a 2). 	1	NA	NA	NA	NA	NA
19-11210948-CA-C	High LDL	LOF	LDLR	NA	NA	NA	NA	likely_lof		NA	1	NA	NA	NA	chr19-11100272-CA-C
19-11213359-CG-C	High LDL	LOF	LDLR	251078	245421	14-Feb-18	Pathogenic	likely_lof		NA	1	NA	NA	NA	chr19-11102683-CG-C
19-11216083-C-A	High LDL	LOF	LDLR	200918	198011	20-Mar-18	Pathogenic	likely_lof		NA	1	NA	NA	NA	chr19-11105407-C-A
19-11216261-GAC-G	High LDL	LOF	LDLR	3731	18770	15-Jun-18	Pathogenic, Pathogenic	likely_lof		NA	2	NA	NA	NA	chr19-11105585-GAC-G
19-11221435-C-T	High LDL	LOF	LDLR	226342	228156	8-May-18	Pathogenic, Pathogenic	likely_lof		1	2	NA	NA	NA	chr19-11110759-C-T
19-11233979-CT-C	High LDL	LOF	LDLR	226388	228201	11-May-17	Pathogenic, Pathogenic	likely_lof	exon is poorly conserved but constitutive	2	NA	NA	NA	NA	NA
19-11210913-G-A	High LDL	ClinVar	LDLR	430745	424291	30-Mar-17	NA	vus	Insufficient evidence	58	1	NA	NA	NA	chr19-11100237-G-A
19-11213375-G-T	High LDL	ClinVar	LDLR	251081	245424	30-Mar-17	NA	vus		NA	1	NA	NA	NA	chr19-11102699-G-T
19-11213381-C-T	High LDL	ClinVar	LDLR	161289	171197	25-Mar-16	NA	vus		NA	3	NA	NA	NA	chr19-11102705-C-T
19-11213390-C-T	High LDL	ClinVar	LDLR	183083	181222	16-Dec-16	NA	vus		NA	1	NA	NA	NA	chr19-11102714-C-T
19-11213463-G-C	High LDL	ClinVar	LDLR	228358	230978	16-Dec-16	NA	vus		NA	1	NA	NA	NA	chr19-11102787-G-C
19-11215925-C-T	High LDL	ClinVar	LDLR	251162	245500	30-Mar-17	NA	vus		6	1	NA	NA	NA	chr19-11105249-C-T
19-11216086-C-A	High LDL	ClinVar	LDLR	251261	245598	25-Mar-16	NA	vus		1	NA	NA	NA	NA	NA
19-11216273-T-G	High LDL	ClinVar	LDLR	251397	245736	5-Nov-16	NA	vus	Insufficient evidence	1	NA	NA	NA	NA	NA
19-11217264-G-A	High LDL	ClinVar	LDLR	200920	198013	22-May-18	NA	vus		3	1	NA	NA	NA	chr19-11106588-G-A
19-11217303-C-T	High LDL	ClinVar	LDLR	161261	171200	30-Mar-17	NA	vus	Insufficient evidence	23	5	NA	NA	NA	chr19-11106627-C-T
19-11217315-C-T	High LDL	ClinVar	LDLR	251446	245782	29-Jun-18	Uncertain significance	vus		12	1	NA	NA	NA	chr19-11106639-C-T
19-11218137-G-A	High LDL	ClinVar	LDLR	251502	245834	16-Dec-16	NA	vus		NA	1	NA	NA	NA	chr19-11107461-G-A
19-11221336-G-A	High LDL	ClinVar	LDLR	251567	245891	30-Mar-17	NA	vus		2	7	NA	NA	NA	chr19-11110660-G-A
19-11221354-G-A	High LDL	ClinVar	LDLR	161282	171206	16-Dec-16	NA	vus		3	NA	NA	NA	NA	NA
19-11221390-G-A	High LDL	ClinVar	LDLR	183105	181246	13-May-18	Likely pathogenic, Uncertain significance	vus	Probably would have used PM2_supporting for this, check on bs3 and bp5	NA	2	NA	NA	NA	chr19-11110714-G-A
19-11221436-G-C	High LDL	ClinVar	LDLR	226343	228157	3-Mar-17	Uncertain significance	vus		NA	1	NA	NA	NA	chr19-11110760-G-C
19-11221457-G-A	High LDL	ClinVar	LDLR	251625	245949	2-Jan-18	NA	vus		1	NA	NA	NA	NA	NA
19-11222214-A-C	High LDL	ClinVar	LDLR	36452	45115	25-Mar-16	NA	vus		6	13	NA	NA	NA	chr19-11111538-A-C
19-11222296-G-A	High LDL	ClinVar	LDLR	256365	256754	30-Mar-17	NA	vus		13	NA	NA	NA	NA	NA
19-11223963-C-A	High LDL	ClinVar	LDLR	226350	228163	25-Mar-16	NA	vus		NA	1	NA	NA	NA	chr19-11113287-C-A
19-11223984-G-A	High LDL	ClinVar	LDLR	228798	230981	30-Mar-17	NA	vus		1	1	NA	NA	NA	chr19-11113308-G-A
19-11224008-T-G	High LDL	ClinVar	LDLR	251747	246061	25-Mar-16	NA	vus	Insufficient evidence	2	NA	NA	NA	NA	NA
19-11224014-G-A	High LDL	ClinVar	LDLR	251752	246066	13-Dec-16	NA	vus		1	NA	NA	NA	NA	NA
19-11224068-C-T	High LDL	ClinVar	LDLR	251775	246089	25-Mar-16	NA	vus	Insufficient evidence	1	NA	NA	NA	NA	NA
19-11224233-G-A	High LDL	ClinVar	LDLR	36456	45119	18-Aug-11	NA	vus		NA	1	NA	NA	NA	chr19-11113557-G-A
19-11224355-G-A	High LDL	ClinVar	LDLR	251876	246190	30-Mar-17	NA	vus		5	NA	NA	NA	NA	NA
19-11224362-A-G	High LDL	ClinVar	LDLR	183117	181259	30-Mar-17	NA	vus		NA	2	NA	NA	NA	chr19-11113686-A-G
19-11224381-C-T	High LDL	ClinVar	LDLR	251886	246200	5-Nov-16	NA	vus		1	2	NA	NA	NA	chr19-11113705-C-T
19-11224438-G-A	High LDL	ClinVar	LDLR	237863	243273	25-Mar-16	NA	vus		1	NA	NA	NA	NA	NA
19-11224443-G-A	High LDL	ClinVar	LDLR	251909	246223	25-Apr-17	NA	vus	Insufficient evidence	NA	1	NA	NA	NA	chr19-11113767-G-A
19-11226771-T-G	High LDL	ClinVar	LDLR	226361	228174	18-Apr-18	Uncertain significance	vus		NA	2	NA	NA	NA	chr19-11116095-T-G
19-11227550-G-T	High LDL	ClinVar	LDLR	237867	243275	5-Nov-16	NA	vus		1	NA	NA	NA	NA	NA
19-11227552-C-T	High LDL	ClinVar	LDLR	438324	431955	2-Jan-18	NA	vus		1	NA	NA	NA	NA	NA
19-11227574-T-C	High LDL	ClinVar	LDLR	226372	228184	16-Dec-16	NA	vus		NA	1	NA	NA	NA	chr19-11116898-T-C
19-11227603-G-A	High LDL	ClinVar	LDLR	373769	360376	30-Mar-17	NA	vus	Insufficient evidence	2	NA	NA	NA	NA	NA
19-11227645-G-T	High LDL	ClinVar	LDLR	161264	171219	25-Oct-17	Uncertain significance	vus		5	27	NA	NA	NA	chr19-11116969-G-T
19-11227665-C-T	High LDL	ClinVar	LDLR	224618	226402	27-Jun-17	Uncertain significance	vus		8	16	NA	NA	NA	chr19-11116989-C-T
19-11230777-T-C	High LDL	ClinVar	LDLR	252083	246378	16-Dec-16	NA	vus	Insufficient evidence	2	NA	NA	NA	NA	NA
19-11230782-G-T	High LDL	ClinVar	LDLR	226376	228189	25-Mar-16	NA	vus		NA	1	NA	NA	NA	chr19-11120106-G-T
19-11230790-T-C	High LDL	ClinVar	LDLR	369855	354097	NA	NA	vus	Insufficient evidence	3	3	NA	NA	NA	chr19-11120114-T-C
19-11230798-G-A	High LDL	ClinVar	LDLR	183127	181269	27-Sep-17	Uncertain significance	vus	Conflicting, but VUS by high confidence lab after Jan 2017	18	14	NA	NA	NA	chr19-11120122-G-A
19-11230801-G-A	High LDL	ClinVar	LDLR	252101	246397	30-Mar-17	NA	vus		1	NA	NA	NA	NA	NA
19-11230820-G-A	High LDL	ClinVar	LDLR	226380	228193	28-Nov-17	NA	vus		2	NA	NA	NA	NA	NA
19-11230877-T-C	High LDL	ClinVar	LDLR	226382	228195	28-Mar-18	Uncertain significance	vus	Conflicting, but VUS by high confidence lab after Jan 2017	1	NA	NA	NA	NA	NA
19-11230888-C-A	High LDL	ClinVar	LDLR	252136	246432	16-Dec-16	NA	vus	Insufficient evidence	1	3	NA	NA	NA	chr19-11120212-C-A
19-11231088-G-T	High LDL	ClinVar	LDLR	226385	228198	25-Mar-16	NA	vus	Insufficient evidence	1	NA	NA	NA	NA	NA
19-11231108-G-A	High LDL	ClinVar	LDLR	252192	246486	16-Dec-16	NA	vus	Insufficient evidence	4	NA	NA	NA	NA	NA
19-11231159-G-A	High LDL	ClinVar	LDLR	183130	181272	7-Jun-17	NA	vus	Insufficient evidence	14	4	NA	NA	NA	chr19-11120483-G-A
19-11233951-G-A	High LDL	ClinVar	LDLR	183133	181275	14-Jun-16	NA	vus	Insufficient evidence	8	1	NA	NA	NA	chr19-11123275-G-A
19-11233969-G-T	High LDL	ClinVar	LDLR	430797	424341	30-Mar-17	NA	vus		1	NA	NA	NA	NA	NA
19-11233991-C-T	High LDL	ClinVar	LDLR	161262	171222	30-Mar-17	NA	vus	Insufficient evidence	2	1	NA	NA	NA	chr19-11123315-C-T
19-11238715-G-T	High LDL	ClinVar	LDLR	252290	246576	25-Mar-16	NA	vus		1	NA	NA	NA	NA	NA
19-11240278-G-A	High LDL	ClinVar	LDLR	36462	45125	2-Nov-17	Uncertain significance, Likely benign	vus		63	10	NA	NA	NA	chr19-11129602-G-A
19-11210979-G-T	High LDL	ClinVar	LDLR	68099	78990	30-Nov-17	Likely benign	likely benign		34	61	NA	NA	NA	chr19-11100303-G-T
19-11210996-C-G	High LDL	ClinVar	LDLR	369857	354078	NA	NA	likely benign		6	NA	NA	NA	NA	NA
19-11217352-G-A	High LDL	ClinVar	LDLR	161279	171202	17-Oct-17	Likely benign	likely benign	Functional studies show no damaging effect, Lack of segregation in affected members of a family, observed in cis with a pathogenic variant, Allele frequency is greater than expected for disorder	27	18	NA	NA	NA	chr19-11106676-G-A
19-11221456-C-T	High LDL	ClinVar	LDLR	369861	354091	NA	NA	likely benign		3	NA	NA	NA	NA	NA
19-11230758-G-T	High LDL	ClinVar	LDLR	252072	246373	29-Aug-17	NA	likely benign		2	2	NA	NA	NA	chr19-11120082-G-T
19-11240240-G-A	High LDL	ClinVar	LDLR	161278	171223	17-Nov-17	Likely benign	likely benign		41	NA	NA	NA	NA	NA
19-11218079-G-A	High LDL	ClinVar	LDLR	183097	181238	29-Dec-17	Benign	benign		50	30	NA	NA	NA	chr19-11107403-G-A
19-11221324-G-A	High LDL	ClinVar	LDLR	224619	226399	12-Jan-18	Benign	benign		293	3	NA	NA	NA	chr19-11110648-G-A
19-11221357-G-A	High LDL	ClinVar	LDLR	161263	171207	5-Oct-17	Benign	benign		126	NA	NA	NA	NA	NA
19-11222182-T-C	High LDL	ClinVar	LDLR	36451	45114	31-May-18	Benign	benign		330	621	NA	NA	NA	chr19-11111506-T-C
19-11222300-G-A	High LDL	ClinVar	LDLR	183138	181250	18-Aug-17	Benign	benign		3274	3753	NA	NA	NA	chr19-11111624-G-A
19-11223961-C-T	High LDL	ClinVar	LDLR	224620	226400	2-Jan-18	Benign	benign		121	11	NA	NA	NA	chr19-11113285-C-T
19-11230809-C-T	High LDL	ClinVar	LDLR	237868	243276	8-Jan-18	Benign	benign		118	NA	NA	NA	NA	NA
19-11231203-G-A	High LDL	ClinVar	LDLR	36460	45123	26-Jan-18	Benign	benign		386	919	NA	NA	NA	chr19-11120527-G-A
19-11226815-AG-A	High LDL	LOF	LDLR	NA	NA	NA	NA	likely_not_lof	reads look good  G homopolymer with del of G	NA	1	NA	NA	NA	chr19-11116139-AG-A
19-11240186-C-T	High LDL	LOF	LDLR	NA	NA	NA	NA	likely_not_lof	Last exon, overhang exon	1	3	NA	NA	NA	chr19-11129510-C-T
19-11241961-A-G	High LDL	LOF	LDLR	NA	NA	NA	NA	likely_not_lof	Last exon, overprinting	1	1	NA	NA	NA	chr19-11131285-A-G
19-11213463-G-A	High LDL	LOF	LDLR	3736	18775	16-Jul-18	Pathogenic, Pathogenic	not_lof	nagnag	NA	1	NA	NA	NA	chr19-11102787-G-A
19-11213463-G-C	High LDL	LOF	LDLR	228358	230978	16-Dec-16	NA	not_lof	nagnag	NA	1	NA	NA	NA	chr19-11102787-G-C
19-11240150-C-CG	High LDL	LOF	LDLR	NA	NA	NA	NA	not_lof	low pext	NA	1	NA	NA	NA	chr19-11129474-C-CG
19-11240285-A-T	High LDL	LOF	LDLR	NA	NA	NA	NA	not_lof	low pext	NA	1	NA	NA	NA	chr19-11129609-A-T
1-55505604-G-A	High LDL	ClinVar	PCSK9	297692	281418	14-Jun-16	NA	vus	PP1_strong, PS4_moderate, PS3_supporting	3	NA	NA	NA	NA	NA
1-55505613-G-T	High LDL	ClinVar	PCSK9	375848	362650	16-Dec-16	NA	vus	Conflicting evidence	1	NA	NA	NA	NA	NA
1-55518374-C-T	High LDL	ClinVar	PCSK9	265933	260609	25-Jul-17	NA	vus		57	125	NA	NA	NA	chr1-55052701-C-T
1-55523779-C-A	High LDL	ClinVar	PCSK9	369875	354066	16-Dec-16	NA	vus		31	NA	NA	NA	NA	NA
1-55524211-C-T	High LDL	ClinVar	PCSK9	403292	389422	5-Dec-17	Likely pathogenic	vus	Reassed because PCSK9 is typically for Low LDL , Reassessed because PCSK9 missense variants are typically for Low LDL	1	1	NA	NA	NA	chr1-55058538-C-T
1-55524222-C-T	High LDL	ClinVar	PCSK9	201128	196756	7-Dec-17	Benign, Uncertain significance	vus		94	2	NA	NA	NA	chr1-55058549-C-T
1-55509693-G-A	High LDL	ClinVar	PCSK9	375844	362654	16-Dec-16	NA	likely benign	Functional studies show no damaging effect, In silico predicts benign, reassessed as VUS	1	NA	NA	NA	NA	NA
11-116661656-G-A	High triglycerides	ClinVar	APOA5	381733	371260	1-Feb-17	Pathogenic	pathogenic	High Confidence Lab	7	26	NA	NA	NA	chr11-116790940-G-A
11-116662399-G-A	High triglycerides	LOF	APOA5	NA	NA	NA	NA	lof		2	NA	NA	NA	NA	NA
11-116661107-C-A	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof	last exon, partial exon conservation/weak gene conservation, high pext	1	NA	NA	NA	NA	NA
11-116661122-G-A	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof	SNV at homopolymer, partial exon conservation, in the last exon, but right on the border of taking out 25% of the protein so kept as likely lof	3	10	NA	NA	NA	chr11-116790406-G-A
11-116661281-C-CG	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
11-116661517-CG-C	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof	pext 1  conservation not great  but OK  in last exon but over 25% of gene	1	2	NA	NA	NA	chr11-116790801-CG-C
11-116661599-C-A	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof		2	NA	NA	NA	NA	NA
11-116661617-A-AG	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
11-116661656-G-A	High triglycerides	LOF	APOA5	381733	371260	1-Feb-17	Pathogenic	likely_lof	pext 1  conservation not great  but OK  in last exon but over 25% of gene	7	26	NA	NA	NA	chr11-116790940-G-A
11-116661662-G-A	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_lof	pext 1  conservation not great  but OK  in last exon but over 25% of gene	NA	2	NA	NA	NA	chr11-116790946-G-A
11-116660951-CTGTT-C	High triglycerides	LOF	APOA5	NA	NA	NA	NA	likely_not_lof	partial exon conservation	NA	1	NA	NA	NA	chr11-116790235-CTGTT-C
8-19796997-CAG-C	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof	pext = 1  1 (LOF)	NA	1	NA	NA	NA	chr8-19939486-CAG-C
8-19797040-G-T	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
8-19805847-G-A	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
8-19809302-G-A	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof	pext = 1  1 (LOF)	NA	1	NA	NA	NA	chr8-19951791-G-A
8-19809427-C-T	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		1	4	NA	NA	NA	chr8-19951916-C-T
8-19810828-TTAAC-T	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		NA	7	NA	NA	NA	chr8-19953317-TTAAC-T
8-19811776-TG-T	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		NA	2	NA	NA	NA	chr8-19954265-TG-T
8-19811847-CAG-C	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr8-19954336-CAG-C
8-19816892-G-A	High triglycerides	LOF	LPL	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
8-19809294-T-A	High triglycerides	LOF	LPL	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
8-19811679-G-A	High triglycerides	ClinVar	LPL	521082	511752	26-Apr-16	NA	vus		8	NA	NA	NA	NA	NA
8-19811733-G-A	High triglycerides	ClinVar	LPL	1522	16561	31-Oct-18	NA	vus		12	36	NA	NA	NA	chr8-19954222-G-A
8-19813385-G-A	High triglycerides	ClinVar	LPL	1530	16569	29-Jun-17	NA	vus		NA	1	NA	NA	NA	chr8-19955874-G-A
8-19813529-A-G	High triglycerides	ClinVar	LPL	1550	16589	3-Dec-17	NA	benign	Found in too many controls	590	NA	NA	NA	NA	NA
8-19819724-C-G	High triglycerides	LOF	LPL	NA	NA	NA	NA	likely_not_lof	last exon, variant is right before the stop codon	5986	7314	NA	NA	NA	chr8-19962213-C-G
8-19797040-G-GT	High triglycerides	LOF	LPL	NA	NA	NA	NA	not_lof	Essential splice site rescue	1	NA	NA	NA	NA	NA
1-156106776-G-A	Lipodystrophy	ClinVar	LMNA	14486	29525	7-May-18	Pathogenic	pathogenic	Used HC lab assessment	1	NA	Used HC lab assessment	Pathogenic	PP3, PP1-strong, PS4, PM5 (p.Arg482Leu and p.Arg482Trp)   The c.1445G>A variant in codon 482 (exon 8 of the RefSeq gene) of the Lamin A/C gene, LMNA, results in the substitution of Arginine to Glutamine. Mutations in the LMNA gene have been found to cause multiple disorders, collectively known as A-type laminopathies, that have overlapping signs and symptoms (23853504, 20074070, OMIM, 16364671).   A-type laminopathies include familial partial lipodystrophy type 2 (FPLD2, also called familial partial lipodystrophy, Dunnigan type), Limb-Girdle muscular dystrophy type 1B, Emery-Dreifuss muscular dystrophy (EDMD), Charcot-Marie-Tooth type 2B1 disease, Hutchinson-Gilford progeria, Heart-hand syndrome, Slovenian type, mandibuloacral dysplasia, Malouf syndrome, and familial dilated cardiomyopathy (23853504, 20074070, OMIM).  To date, no clear genotype-phenotype correlations have been identified (23853504, 20074070).  The c.1445G>A variant has been identified in multiple individuals over multiple generations in families with clinical diagnoses of FPLD2 (22700598, 10868844, 10999845, 10587585, 10739751, 10655060).  This variant was also found in the homozygous state in an individual with FPLD2 and autosomal recessive-EDMD (23313286).  A different amino acid change at codon 482, Arg482Trp, has also been shown to segregate with FPLD2 (23853504, 22700598, 10999845, 10739751, 10655060). Approximately 75% of patients with FPLD2 have a mutation at Arg482, making it a mutational hotspot for FPLD2 (16364671).  Multiple lines of computational evidence (SIFT, LRT, MutationTaster, FATHMM, MetaSVM, MetalR, GERP, CADD) predict the c.1445G>A variant is probably damaging to the protein structure, function, or protein-protein interaction. Indeed, functional studies of the Arg482Gln mutant protein, as well as the Arg482Trp protein, demonstrated a failure of adipocyte cell differentiation (16415042). A transgenic mouse harboring the Arg482Gln mutation recapitulates the FPLD2 phenotype and studies confirmed a lack of adipocyte renewal (19201734).	NA
1-156105812-C-T	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
1-156108540-C-T	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	likely_lof	pext = 0.43 , homopolymer with SNV variant in 50% of tx 	NA	4	NA	NA	NA	chr1-156138749-C-T
1-156107470-G-A	Lipodystrophy	ClinVar	LMNA	163878	172489	23-Apr-18	NA	vus	Assessed by HC lab, but reassessed due to high frequency; Uncertain significance - conflicting evidence:  The p.Arg545His variant in LMNA has been reported in 1 individual with lipodystrophy (PMID: 28074886), but has been identified in 0.05% (41/79748) of European (non-Finnish) chromosomes and other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP  rs142191737). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 163878). In vitro functional studies provide some evidence that the p.Arg545His variant may slightly impact protein function (PMID: 22918509). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Arg545His have been reported in association with disease in the literature and the variant is located in a region of LMNA that is thought to be essential to protein folding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 28663758). In summary, the clinical significance of the p.Arg545His variant is uncertain. ACMG/AMP Criteria applied: PP3, PS3_supporting, PM1_supporting, BA1 (Richards 2015)., Assessed by HC lab, but reassessed due to high frequency; Uncertain significance - conflicting evidence:  The p.Arg545His variant in LMNA has been reported in 1 individual with lipodystrophy (PMID: 28074886), but has been identified in 0.05% (41/79748) of European (non-Finnish) chromosomes and other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP  rs142191737). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 163878). In vitro functional studies provide some evidence that the p.Arg545His variant may slightly impact protein function (PMID: 22918509). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Arg545His have been reported in association with disease in the literature and the variant is located in a region of LMNA that is thought to be essential to protein folding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 28663758). In summary, the clinical significance of the p.Arg545His variant is uncertain. ACMG/AMP Criteria applied: PP3, PS3_supporting, PM1_supporting, BA1 (Richards 2015)., After reassessment this variant is given a VUS assessment	4	31	Assessed by HC lab, but reassessed due to high frequency; Uncertain significance - conflicting evidence:  The p.Arg545His variant in LMNA has been reported in 1 individual with lipodystrophy (PMID: 28074886), but has been identified in 0.05% (41/79748) of European (non-Finnish) chromosomes and other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP  rs142191737). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 163878). In vitro functional studies provide some evidence that the p.Arg545His variant may slightly impact protein function (PMID: 22918509). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Arg545His have been reported in association with disease in the literature and the variant is located in a region of LMNA that is thought to be essential to protein folding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 28663758). In summary, the clinical significance of the p.Arg545His variant is uncertain. ACMG/AMP Criteria applied: PP3, PS3_supporting, PM1_supporting, BA1 (Richards 2015).	NA	NA	chr1-156137679-G-A
1-156108298-C-T	Lipodystrophy	ClinVar	LMNA	14517	29556	21-Dec-17	NA	benign	The p.Ser573Leu variant in LMNA has been reported in 1 European individual with familial partial lipodystrophy (PMID: 17250669), but has been identified in 0.04% (4/10102) of Ashkenazi Jewish chromosomes and other populations at slightly lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs60890628). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 14517). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as benign for familial partial lipodystrophy in an autosomal dominant manner based on its frequency in the general population. ACMG/AMP Criteria applied: BA1 (Richards 2015).	14	2	The p.Ser573Leu variant in LMNA has been reported in 1 European individual with familial partial lipodystrophy (PMID: 17250669), but has been identified in 0.04% (4/10102) of Ashkenazi Jewish chromosomes and other populations at slightly lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs60890628). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 14517). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as benign for familial partial lipodystrophy in an autosomal dominant manner based on its frequency in the general population. ACMG/AMP Criteria applied: BA1 (Richards 2015).	NA	NA	chr1-156138507-C-T
1-156096000-GA-G	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	likely_not_lof	Genotyping error	1	NA	NA	NA	NA	NA
1-156096701-T-TC	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	likely_not_lof	somewhat GC rich  this exon seems to have low pext score  5	NA	1	NA	NA	NA	chr1-156126910-T-TC
1-156106992-T-TGCGTACGGCTCTCATCAACTCCACTGGGGAAGTAAGTA	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	likely_not_lof	Within the 50 penultimate BP	1	NA	NA	NA	NA	NA
1-156096374-C-A	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	not_lof	minority of tx (only in ensembl), weak exon conservation, low pext - 5	2	NA	NA	NA	NA	NA
1-156106159-G-A	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	not_lof	Only a splice donor variant in a single transcript. Low pext	NA	2	NA	NA	NA	chr1-156136368-G-A
1-156106981-C-T	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	not_lof	Only in one transcript and low pext	NA	5	NA	NA	NA	chr1-156137190-C-T
1-156108466-T-TG	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	not_lof	Last exon	1	NA	NA	NA	NA	NA
1-156109560-G-C	Lipodystrophy	LOF	LMNA	NA	NA	NA	NA	not_lof	unrecognized rescue site 18bp into exon  pext = 0.01	NA	2	NA	NA	NA	chr1-156139769-G-C
3-12475610-C-T	Lipodystrophy	ClinVar	PPARG	8136	23175	14-Jun-16	NA	pathogenic	Absent from controls, Well-established functional studies show a deleterious effect, Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease	1	NA	The p.Pro495Leu variant (sometimes called p.Pro467Leu) in PPARG has been reported in 2 individuals with lipodystrophy, segregated with disease in these 2 affected relatives from 1 family (PMID: 10622252), and has been identified in 0.0009% (1/113420) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs121909244). This variant has also been reported in ClinVar as a VUS, likely pathogenic, and pathogenic (Variation ID: 8136). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population.  In vitro functional studies provide some evidence that the p.Pro495Leu variant may impact protein function (PMID: 10622252). However, these types of assays may not accurately represent biological function. Animal models in mice have shown that this variant causes lipodystrophy (PMID: 15254591). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. This variant was found to be de novo in 1 individual with confirmed paternity and maternity (PMID: 10622252). The p.Pro495Leu is located in a region of PPARG that is essential to protein folding and stability, suggesting that this variant is in a functional domain and supports pathogenicity (PMID: 10622252). In summary, this variant meets criteria to be classified as pathogenic for lipodystrophy in an autosomal dominant manner based on a mouse model for this variant having the same phenotype as well as a de novo occurrence of this variant in an affected patient. ACMG/AMP Criteria applied: PS2, PS3, PM2, PM1, PP3 (Richards 2015).	Likely Pathogenic	PM2 (1 copy in ENF), PP3, PM1(transactivation domain), PS3(P495L shows dominant negative effect during coactivator recruitment in 12663460 and 10622252,17227883 ), two families reported with lipodystrophy (10622252,12663460). No PP1 because only 1 meiosis in 1 family, No PS2 because no literature.	NA
3-12434213-G-A	Lipodystrophy	ClinVar	PPARG	436397	428116	8-Aug-16	NA	likely pathogenic		1	NA	The p.Arg194Gln variant in PPARG has been reported in 2 individuals suspected to have Familial Partial Lipodystrophy (PMID: 27749844), and has also been reported likely pathogenic in ClinVar (Variation ID: 436397). This variant was absent from large population studies. In vitro functional studies provide some evidence that the p.Arg194Gln variant may eliminate protein function (PMID: 27749844). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional variant, causing a different amino acid change at the same position, p.Arg194Trp, has been reported in association with disease in the literature, slightly supporting that a change at this position may not be tolerated (PMID: 17299075; DOI: 10.1530/endoabs.41.GP59). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS3, PM2, PP3, PM5_Supporting (Richards 2015).	Likely Pathogenic	PP3, PM2, PS3_mod(27749844 showed p.Arg194Gln variant abolished PPAR_ transactivation activity in standard assays), PM5(R194W is LP: PP3, PM2(1 allele in NFE), PS3(17299075 showed R194W did not bind DNA and was transcriptionally inactive))	NA
3-12421431-G-A	Lipodystrophy	LOF	PPARG	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
3-12447410-G-T	Lipodystrophy	LOF	PPARG	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
3-12447507-C-G	Lipodystrophy	LOF	PPARG	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
3-12458202-G-A	Lipodystrophy	LOF	PPARG	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
3-12458364-T-A	Lipodystrophy	LOF	PPARG	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr3-12416865-T-A
3-12458536-C-T	Lipodystrophy	LOF	PPARG	NA	NA	NA	NA	lof		NA	2	NA	NA	NA	chr3-12417037-C-T
3-12475484-AC-A	Lipodystrophy	ClinVar	PPARG	436405	428125	22-Jul-16	NA	vus	Insufficient evidence	1	NA	Insufficient evidence	NA	NA	NA
3-12475484-AC-A	Lipodystrophy	LOF	PPARG	436405	428125	22-Jul-16	NA	not_lof	Last exon	1	NA	NA	NA	NA	NA
2-21228457-G-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21228525-CATTT-C	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for MNV  50% tx  pext=1	NA	1	NA	NA	NA	chr2-21005653-CATTT-C
2-21228587-G-C	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	NA	2	NA	NA	NA	chr2-21005715-G-C
2-21228589-A-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21228891-CA-C	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	NA	11	NA	NA	NA	chr2-21006019-CA-C
2-21228959-C-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for MNV  50% tx  pext=1	NA	1	NA	NA	NA	chr2-21006087-C-T
2-21228972-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21229501-AG-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for frame restore  50% of tx  pext=1	1	2	NA	NA	NA	chr2-21006629-AG-A
2-21229937-G-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21230237-G-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for MNV  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21007365-G-T
2-21230323-G-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21231228-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21232140-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	NA	2	NA	NA	NA	chr2-21009268-G-A
2-21232176-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	2	4	NA	NA	NA	chr2-21009304-G-A
2-21232182-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	NA	2	NA	NA	NA	chr2-21009310-G-A
2-21232203-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21009331-G-A
2-21232760-TC-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	NA	2	NA	NA	NA	chr2-21009888-TC-T
2-21232920-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21233193-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21233453-TGTAC-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for frame restore  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21010581-TGTAC-T
2-21233487-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for MNV  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21010615-G-A
2-21233706-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21233718-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		2	NA	NA	NA	NA	NA
2-21233814-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21233911-AG-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for frame restore  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21011039-AG-A
2-21234172-AAC-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	1	1	NA	NA	NA	chr2-21011300-AAC-A
2-21234696-TAGATGCCCCAG-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21236242-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for MNV  50% of tx  pext=1	1	1	NA	NA	NA	chr2-21013370-G-A
2-21236251-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for MNV  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21013379-G-A
2-21238330-GT-G	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	no reads  check for frame restore  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21015458-GT-G
2-21238362-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21245797-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21022925-C-A
2-21250737-AG-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	pext = 1  1 (LOF)	NA	2	NA	NA	NA	chr2-21027865-AG-A
2-21255253-A-T	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	pext = 1  1 (LOF)	NA	1	NA	NA	NA	chr2-21032381-A-T
2-21255263-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	pext = 1  1 (LOF)	1	7	NA	NA	NA	chr2-21032391-G-A
2-21258581-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
2-21260958-C-A	Low LDL	LOF	APOB	NA	NA	NA	NA	lof	pext = 1  1 (LOF)	NA	2	NA	NA	NA	chr2-21038086-C-A
2-21235074-T-A	Low LDL	LOF	APOB	NA	NA	NA	NA	likely_lof	SNV at homopolymer  50% of tx  pext=1	NA	1	NA	NA	NA	chr2-21012202-T-A
2-21246396-C-T	Low LDL	LOF	APOB	NA	NA	NA	NA	likely_lof	Essential splice site rescue	1	NA	NA	NA	NA	NA
2-21224973-CA-C	Low LDL	LOF	APOB	NA	NA	NA	NA	likely_not_lof	last exon, weak/partial exon conservation, pext=1	1	NA	NA	NA	NA	NA
2-21225192-GA-G	Low LDL	LOF	APOB	NA	NA	NA	NA	likely_not_lof	last exon, weak/partial exon conservation, pext=1 	1	NA	NA	NA	NA	NA
2-21225235-G-T	Low LDL	LOF	APOB	NA	NA	NA	NA	likely_not_lof	last exon, weak/partial exon conservation, pext=1 	1	NA	NA	NA	NA	NA
2-21225765-G-A	Low LDL	LOF	APOB	NA	NA	NA	NA	not_lof	Last exon	3	NA	NA	NA	NA	NA
2-21263809-C-T	Low LDL	LOF	APOB	NA	NA	NA	NA	not_lof	pext = 1  unrecognized alt . donor site within 6 bp  5 (don't necessarily agree with this in the case of this gene)	NA	1	NA	NA	NA	chr2-21040937-C-T
1-55509648-GT-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr1-55043975-GT-G
1-55512222-C-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		26	NA	NA	NA	NA	NA
1-55512243-CTT-C	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr1-55046570-CTT-C
1-55517991-C-CAT	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		13	NA	NA	NA	NA	NA
1-55518047-ATG-A	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr1-55052374-ATG-A
1-55518059-AGGACGGGACCC-A	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr1-55052386-AGGACGGGACCC-A
1-55518324-CCAGCAAGT-C	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof	alt splice acceptor within 6 bp (nagnag) - 5	NA	1	NA	NA	NA	chr1-55052651-CCAGCAAGT-C
1-55518419-GT-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		4	NA	NA	NA	NA	NA
1-55518437-A-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr1-55052764-A-T
1-55521679-TC-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof	partial exon conservation	NA	1	NA	NA	NA	chr1-55056006-TC-T
1-55521682-GA-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof	partial exon conservation	NA	1	NA	NA	NA	chr1-55056009-GA-G
1-55523037-C-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr1-55057364-C-T
1-55523148-TCA-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		3	NA	NA	NA	NA	NA
1-55523786-GC-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof	partial exon conservation  2	NA	2	NA	NA	NA	chr1-55058113-GC-G
1-55523884-T-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
1-55525196-CTT-C	Low LDL	LOF	PCSK9	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
1-55505543-G-A	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	quite GC rich  partial exon conservation  Likely LOF, pext = 0.93	NA	1	NA	NA	NA	chr1-55039870-G-A
1-55505582-TC-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	Deletion in a some what repetitive region and high GC content. Also looks like there is another deletion upstream, but is not consistently in cis or trans, so this is likely a genotyping error. Also in a poorly conserved exon	1	NA	NA	NA	NA	NA
1-55505598-G-GCGCA	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	quite GC rich  partial exon conservation  Likely LOF, pext = 0.93	NA	10	NA	NA	NA	chr1-55039925-G-GCGCA
1-55505697-AC-A	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	quite GC rich  partial exon conservation  Likely LOF, pext = 0.93	NA	2	NA	NA	NA	chr1-55040024-AC-A
1-55518085-G-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	unrecognized alt donor site  12 bp away  Likely LOF	6	15	NA	NA	NA	chr1-55052412-G-T
1-55518377-G-GA	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	quite GC rich - likely LOF	NA	2	NA	NA	NA	chr1-55052704-G-GA
1-55523188-G-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
1-55527146-GC-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_lof	partial exon conservation  pext=0.93	NA	1	NA	NA	NA	chr1-55061473-GC-G
1-55524321-G-T	Low LDL	LOF	PCSK9	NA	NA	NA	NA	likely_not_lof	Essential splice site rescue	1	NA	NA	NA	NA	NA
1-55512320-G-GT	Low LDL	LOF	PCSK9	NA	NA	NA	NA	not_lof	Essential splice site rescue	5	NA	NA	NA	NA	NA
1-55516888-G-GA	Low LDL	LOF	PCSK9	NA	NA	NA	NA	not_lof	Transcript error - minority of transcripts and weak conservation	80	NA	NA	NA	NA	NA
1-55518321-A-C	Low LDL	LOF	PCSK9	NA	NA	NA	NA	not_lof	delINS but complete knockdown of splice acceptor site predicted by alamut  LOF	NA	1	NA	NA	NA	chr1-55052648-A-C
1-55518321-A-G	Low LDL	LOF	PCSK9	NA	NA	NA	NA	not_lof	Essential splice site rescue	2	NA	NA	NA	NA	NA
1-55527230-G-A	Low LDL	LOF	PCSK9	NA	NA	NA	NA	not_lof	Essential splice site rescue, strong alt (59%) splice site predicted  partial exon conservation PLUS end of penultimate exon	1	37	NA	NA	NA	chr1-55061557-G-A
7-44187429-G-A	MODY	ClinVar	GCK	16134	31173	12-Jun-17	Pathogenic	pathogenic	Used HC lab assessment	1	1	Used HC lab assessment	Pathogenic	PS2 (24323243, de novo with proven paternity/maternity), PP1_strong (1502186, 5 meioses), PP4 (24323243, 24735133, 1 each using MODY criteria), PM2 (1 copy in gnomAD), PP3 (Revel = 0.966 and all tools say damaging) (TP 20190728)	chr7-44147830-G-A
7-44189362-C-T	MODY	ClinVar	GCK	36243	44907	11-Oct-17	Pathogenic	pathogenic	Used HC lab assessment	1	NA	Used HC lab assessment	Pathogenic	PS3, PS4, PP1-strong, PM2, PP3 (KM 8/10/18) The c.676G>A variant in codon 226 (exon 7 of the RefSeqGene and exon 6 of NM_000162.3) of the glucokinase gene, GCK, results in the substitution of Valine to Methionine. Missense mutations in GCK, including ones in this exon, have been reported in patients with Maturity-Onset Diabetes of the Young, Type 2 (MODY2, also called GCK-MODY) (PMID: 19790256). The c.676G>A variant was not observed in the NHLBI Exome Sequencing Project, 1000 Genomes Project, or Genome Aggregation (gnomAD) databases; however, this variant has been reported in the literature in patients with a clinical picture consistent with GCK-MODY (PMID: 9049484, 17079173, 16602010, 16965331, 22335469, 25306193, 25555642, 27634015, 28663157, 25015100), with evidence of co-segregation with a GCK-MODY phenotype in six families (PMID: 9049484, 17079173).  Additionally, multiple lines of computational evidence (SIFT, Polyphen, MutationTaster, LRT, FATHMM, MetaSVM, MetalR, CADD, GERP, REVEL) predict the c.676G>A variant is probably damaging to the protein structure, function, or protein-protein interaction. Indeed, the p.Val226Met protein was found to have significantly reduced enzymatic activity (PMID: 25015100, 1052565) and affects ATP affinity (PMID: 10426385).
	NA
7-44189576-G-A	MODY	ClinVar	GCK	426122	415104	7-Nov-17	Pathogenic	pathogenic	Used HC lab assessment	1	2	Used HC lab assessment	Pathogenic	PS4, PM1, PM2, PP1-mod, PP3 (4/19/18) The c.571C>T variant in codon 191 (exon 6) of the glucokinase gene, GCK, results in the substitution of Arginine to Tryptophan. Missense mutations in GCK, including ones in exon 6, have been reported in patients with Maturity-Onset Diabetes of the Young, Type 2 (MODY2, also called GCK-MODY) (19790256). The c.571C>T variant was not observed in the NHLBI Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium databases; however, the c.571C>T variant was previously identified in individuals with a MODY2 phenotype of Korean, Norwegian, Belgian, Brazilian, French, Japanese, Italian, and British descent (16632067, 18399931, 16965331, 23295292, 18411240, 22060211, 11508276, 10753050) .  Other amino acid substitutions at this residue, p.Arg191Gln and p.Arg191Leu, have been found in individuals with a MODY2 phenotype (19790256, 11508276, 16444761, 19309449).  Additionally, multiple lines of computational evidence (LRT, MutationTaster, FATHMM, MetaSVM, MetalR, Provean, GERP, CADD) predict this variant is probably damaging to the protein structure, function, or protein-protein interaction. The c.571C>T variant is located within the small domain of the protein, a region considered to be a mutational hotspot (18382660). 	chr7-44149977-G-A
7-44189585-C-T	MODY	Review	GCK	NA	NA	NA	NA	pathogenic		1	1	PP1_strong, PM2, PS4_moderate, PP3, PM1_supporting, PS3_supporting. 10.1007/s13410-018-0658-6: variant found in 4 relatives from MODY family (2 HOM, 2 Het), father is affected but no sample was given. 0.005% (1/18390) of East Asian chromosomes.This individual is from study cohort. 10.1007/s13410-018-0658-6 : variant found in 4 relatives from Eqyptian MODY family (2 HOM, 2 Het), father is affected but no sample was given. revel = 0.933 and well conserved, no effect on splicing.	Pathogenic	PS4 (22 families in Osbak 19790256 including from 12050210, 12955723, 8933019, 831448, 14517956), PM2 (1 copy in gnomAD), PP3 (Revel = 0.933, DANN = 0.9993, damaging in FATHMM, FATHMM-MKL, MetaSVM, LRT, SIFT, Provean, medium in Mutation assessor), PP4 (well-phenotyped probands included), PP1_strong (8933019--4-5 [if include ungenotyped affected obligate carrier father of two boys with hz NDM one het daughter, 8314448--5) (TP 20190728)	chr7-44149986-C-T
7-44189591-G-A	MODY	ClinVar	GCK	16133	31172	1-Oct-18	Pathogenic	pathogenic	Used HC lab assessment	NA	1	Used HC lab assessment	Pathogenic	PVS1, PP1_strong (17573900, 4 meioses in 2 families), PM2 (absent in gnomAD), PP4 (17573900) (TP 20190728)	chr7-44149992-G-A
7-44189603-C-T	MODY	ClinVar	GCK	129144	134590	31-Oct-18	NA	pathogenic	The p.Val182Met variant in GCK has been reported in at least 9 individuals with maturity-onset diabetes of the young (MODY) type 2, segregated with disease in 4 affected relatives from 2 families (PMID: 29510678, 20337973, 21395678, 25082184, 23771172, 25306193, 25494859), and was absent from large population studies. Animal models in mice have shown that this variant causes MODY type 2 (15102714, 18056790). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for MODY type 2 in an autosomal dominant manner based on the phenotype of mouse models being consistent with human disease, the increased prevalence of the variant in affected individuals, including relatives, compared to controls, and computational evidence. ACMG/AMP Criteria applied: PS3_PM2, PS4_moderate, PP3, PP1 (Richards 2015).	NA	1	The p.Val182Met variant in GCK has been reported in at least 9 individuals with maturity-onset diabetes of the young (MODY) type 2, segregated with disease in 4 affected relatives from 2 families (PMID: 29510678, 20337973, 21395678, 25082184, 23771172, 25306193, 25494859), and was absent from large population studies. Animal models in mice have shown that this variant causes MODY type 2 (15102714, 18056790). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for MODY type 2 in an autosomal dominant manner based on the phenotype of mouse models being consistent with human disease, the increased prevalence of the variant in affected individuals, including relatives, compared to controls, and computational evidence. ACMG/AMP Criteria applied: PS3_PM2, PS4_moderate, PP3, PP1 (Richards 2015).	Pathogenic	PS3 (15102714, 18056790), PM2 (absent from gnomAD), PS4_moderate (29510678, 20337973, 25082184, 23771172, 25306193, 25494859, 5 cases), PP3 (Revel = 0.937, disease causing MT, damaging by FATHMM, FATHMM-MKL, MetaSVM, MetalR, SIFT, Provean, DANN = 0.9991), PP1_supporting (29510678, 25494859, 1 meisosis each in 2 families)	chr7-44150004-C-T
7-44191917-G-A	MODY	Review	GCK	NA	NA	NA	NA	likely pathogenic		NA	2	PVS1, PM2. Nonsense mutation that is predicted to undergo NMD, exon is present in biologically relevant transcripts. Absent from gnomAD.	Likely Pathogenic	PVS1, PM2 (absent from gnomAD) (TP 20190728)	chr7-44152318-G-A
7-44192019-C-T	MODY	ClinVar	GCK	36209	44873	12-Jul-18	NA	likely pathogenic		2	NA	The p.Gly72Arg variant in GCK has been reported in at least 12 individuals (including 2 Mediterranean, 2 Scandinavian, 2 Spanish, 1 Italian, 1 Czech, 1 Turkish, 1 Slovakian, 1 Norwegian, and 1 Asian individuals) with Monogenic Diabetes, segregated with disease in 6 affected relatives from 3 families (PMID: 27106716, 25015100, 22493702, 18399931, 10447526, 12955723, 20337973, 17573900, 15305805), and has been identified in 0.006155% (1/16248) of African chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922289). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported pathogenic in ClinVar (Variation ID: 36209). In vitro functional studies provide some evidence that the p.Gly72Arg variant may impact protein activity and interactions with a regulatory protein (PMID: 21831042, 22028181, 17389332, 19187021). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Gly72Arg is located in a region of GCK that is essential to ATP binding and associated with hypoglycemia, suggesting that this variant is in an important functional domain and slightly supports pathogenicity (PMID: 15305805, 19187021). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS3_moderate, PS4_Moderate, PP1_Moderate, PM2_Supporting, PP3, PM1_Supporting (Richards 2015).	Pathogenic	PS4 (at least 9 families in 27106716, 25015100, 22493702, 18399931, 10447526, 12955723, 17573900, 15305805), PS3 (21831042--changes in fluorescence, 22028181-->35% lower specific activity, 17389332--evidence loss GK activity, 19187021--decreased enzyme activity), PP3 (REVEL = 0994, DANN = 0.9993, damaging by MT, FATHMM, FATHMM-MKL, MetSVM, MetalR, LRT, SIFT Provean, MA), PP1_strong (5 meioses in 3 families:  10447526 (3), 17573900 (1), 15305805 (1)), PM2 (1 copy in gnomAD), PM1 (19187021--affect access to allosteric site) (TP 201907280	NA
7-44192980-C-T	MODY	ClinVar	GCK	393453	380272	21-Dec-17	NA	likely pathogenic	The p.Arg43His variant in GCK has been reported in at least 8 individuals (including 1 German, 1 Slovakian, 1 Swiss, 1 Cyproit, and 1 Hispanic individuals) with Monogenic Diabetes, segregated with disease in 6 affected relatives from 2 family (PMID: 11942313, 24430320, 11942313, 22611063, 22493702, 27106716; DOI:10.3252/pso.eu.54espe.2015; Shammas et al. 2012), and has been identified in 0.002891% (1/34592) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs764232985). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 393453). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional pathogenic variant, resulting in a different amino acid change at the same position, p.Arg43Cys, has been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 21348868, 30592380, 21521320, 23771172, 19790256, 25015100/Variation ID: 585911). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS4_Moderate, PM5, PM2_Supporting, PP3, PP1_moderate (Richards 2015).	1	1	The p.Arg43His variant in GCK has been reported in at least 8 individuals (including 1 German, 1 Slovakian, 1 Swiss, 1 Cyproit, and 1 Hispanic individuals) with Monogenic Diabetes, segregated with disease in 6 affected relatives from 2 family (PMID: 11942313, 24430320, 11942313, 22611063, 22493702, 27106716; DOI:10.3252/pso.eu.54espe.2015; Shammas et al. 2012), and has been identified in 0.002891% (1/34592) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs764232985). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 393453). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. One additional pathogenic variant, resulting in a different amino acid change at the same position, p.Arg43Cys, has been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 21348868, 30592380, 21521320, 23771172, 19790256, 25015100/Variation ID: 585911). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PS4_Moderate, PM5, PM2_Supporting, PP3, PP1_moderate (Richards 2015).	Pathogenic	PS3, PS4, PM5 (Arg43Cys is P per PS3, PS4, PM2, PM5, PP3), PP1, PP3  (10/19/18 KM). Variant review from interpretation of Arg43Cys.  Looks like LP (not P) interp bc missing fxnl studies demonstrating decreased thermostability compared to wildtype protein, indicating overall decreased protein stability (PMID: 25015100, 22611063).	chr7-44153381-C-T
7-44191874-TCAGCAGTG-T	MODY	LOF	GCK	NA	NA	NA	NA	likely_lof	Reads look good. mean pext is low  but conservation is fine and pext in liver is 6.19E-01 and in pancreas is 5.10E-01	NA	1	NA	NA	NA	chr7-44152275-TCAGCAGTG-T
7-44191917-G-A	MODY	LOF	GCK	NA	NA	NA	NA	likely_lof	low mean pext 5.9480e-02 but 6.19E-01 in liver and 5.10E-01 in pancreas  reads look good  conservation good	NA	2	NA	NA	NA	chr7-44152318-G-A
7-44184747-C-A	MODY	ClinVar	GCK	36202	44866	29-May-18	NA	vus	Uncertain significance - insufficient evidence: The p.Met462Ile variant in GCK has not been previously reported in individuals with maturity-onset diabetes of the young (MODY) type 2 but has been identified in 0.004028% (5/124138) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922285). This variant has also been reported in ClinVar (VariationID: 36202) as a VUS by Athena Diagnostics Inc and as likely pathogenic by Integrated Genetics; the former lab also reported one individual with the variant and MODY type 2. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein.  In summary, the clinical significance of the p.Met462Ile variant is uncertain. ACMG/AMP Criteria applied: BS1 (Richards 2015).	NA	18	Uncertain significance - insufficient evidence: The p.Met462Ile variant in GCK has not been previously reported in individuals with maturity-onset diabetes of the young (MODY) type 2 but has been identified in 0.004028% (5/124138) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922285). This variant has also been reported in ClinVar (VariationID: 36202) as a VUS by Athena Diagnostics Inc and as likely pathogenic by Integrated Genetics; the former lab also reported one individual with the variant and MODY type 2. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein.  In summary, the clinical significance of the p.Met462Ile variant is uncertain. ACMG/AMP Criteria applied: BS1 (Richards 2015).	NA	NA	chr7-44145148-C-A
7-44185189-G-A	MODY	ClinVar	GCK	36182	44846	3-Dec-15	NA	vus		1	NA	Uncertain significance - insufficient evidence: The p.Ala387Val variant in GCK has been reported in at least 4 individuals (including 1 Czech individual, 1 Asian individual, and 1 Caucasian individual from the UK) with Monogenic Diabetes (PMID: 14517956, 19790256, 20337973), and has been identified in 0.003400% (1/29414) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193921338). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a dominant frequency for a disease with clinical variability/reduced penetrance. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36182). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Ala387Val have been reported in association with disease in ClinVar, suggesting that this variant is in an important functional domain and slightly supports pathogenicity (Variation ID: 435300, 36180, 36179). Two additional variants (p.Ala387Glu and p.Ala387Thr) causing a different amino acid change at the same position have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 19790256; Variation ID: 36181). The number of missense variants reported in GCK in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary,the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied:  PM2_Supporting, PP3, PS4_Supporting, (Richards 2015).	NA	NA	NA
7-44185216-G-C	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3. 0.0009% (1/105532) of European (non-Finnish) chromosomes. This individual is from study cohort. revel = 0.901 and well conserved.	NA	NA	NA
7-44185325-T-G	MODY	Review	GCK	NA	NA	NA	NA	vus		NA	7	Uncertain significance - conflicting evidence: BS4, PM2, BP4. Identified in 0.001809% (2/110580) of European (non-Finnish) chromosomes **Annotated as p.Thr343Pro. REVEL=0.296; very poorly conserved.	NA	NA	chr7-44145726-T-G
7-44186062-C-A	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3. Absent: 0.0008947% (1/111772) of European (non-Finnish) chromosomes on gnomAD but the 1 het is from the 52K dataset. REVEL=0.792; AA is well conserved, last nt in exon--expected to abolish donor splice site	NA	NA	NA
7-44187276-T-C	MODY	Review	GCK	NA	NA	NA	NA	vus		10	11	Uncertain significance - conflicting evidence: BA1, PP3. 0.01132% (4/35329) of Latino chromosomes; 0.01981% (7/35332) of Latino chromosomes on gnomAD but 3 hets are from 52K dataset. REVEL=0.89; conserved.	NA	NA	chr7-44147677-T-C
7-44187339-C-T	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3. 0.005% (1/18388) of East Asian chromosomes. This individual is from study cohort. revel = 0.99 and well conserved.	NA	NA	NA
7-44187364-G-A	MODY	ClinVar	GCK	393451	380270	21-Sep-17	NA	vus	Uncertain significance - insufficient evidence: The p.Arg250Cys variant in GCK has been reported in at least 5 families with MODY (PMID: 15448103, 20337973, 19790256) and was absent from large population studies. This variant has also been reported in ClinVar (VariationID: 393451) as likely pathogenic by Translational Genomics Laboratory and as a VUS by Athena Diagnostics Inc. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, PP3, PS4_supporting (Richards 2015).	NA	2	Uncertain significance - insufficient evidence: The p.Arg250Cys variant in GCK has been reported in at least 5 families with MODY (PMID: 15448103, 20337973, 19790256) and was absent from large population studies. This variant has also been reported in ClinVar (VariationID: 393451) as likely pathogenic by Translational Genomics Laboratory and as a VUS by Athena Diagnostics Inc. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, PP3, PS4_supporting (Richards 2015).	NA	NA	chr7-44147765-G-A
7-44187396-T-C	MODY	Review	GCK	NA	NA	NA	NA	vus		5	NA	Uncertain significance - conflicting evidence: BA1, PS4_supporting. 0.010886% (2/18380) of East Asian chromosomes: 0.05441% (10/18380) of East Asian chromosomes on gnomAD, but 8/10 hets were from 52K dataset.	NA	NA	NA
7-44187403-C-T	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3, PP1. Absent: 0.003266% (1/30614) of South Asian chromosomes, but the 1 het is from the 52K dataset. REVEL=0.853; well conserved.	NA	NA	NA
7-44189570-C-G	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3. Absent: 0.006158% (1/16240) of African chromosomes but het in gnomAD is from 52K dataset. REVEL=0.811; well conserved in mammals; last AA in exon but not expected to impact splicing.	NA	NA	NA
7-44190598-C-T	MODY	ClinVar	GCK	36217	44881	18-Aug-11	NA	vus		1	NA	Uncertain significance - insufficient evidence: The p.Gly147Asp variant in GCK has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 36217), and has been identified in 0.002892% (1/34580) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922296). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and as a VUS in the literature (Variation ID: 36217; PMID: 27080136). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The number of missense variants reported in GCK in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP2, PP3 (Richards 2015).	NA	NA	NA
7-44190644-C-T	MODY	Review	GCK	NA	NA	NA	NA	vus		2	NA	Uncertain significance - insufficient evidence: PM2. Absent: 0.006155% (1/16248) of African chromosomes and 0.0008798% (1/113664) of European (non-Finnish) chromosomes, but the 2 hets are from 52K dataset	NA	NA	NA
7-44190668-C-T	MODY	ClinVar	GCK	211073	207484	1-Jun-17	NA	vus	Uncertain significance - insufficient evidence: The p.Asp124Asn variant in GCK has been reported in at least 6 individuals (including 1 Polish, 1 Czech, 1 German, and 2 Caucasian individuals) with Monogenic Diabetes (PMID: 27106716, 22773699, 24918535, 20337973; DOI: 10.2337/db18-1509-P), and has been identified in 0.002893% (1/34564) of Latino chromosomes and 0.0008805% (1/113574) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs759072800). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 211073). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The number of missense variants reported in GCK in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4_Moderate, PM2_Supporting, PP2, PP3 (Richards 2015).	1	2	Uncertain significance - insufficient evidence: The p.Asp124Asn variant in GCK has been reported in at least 6 individuals (including 1 Polish, 1 Czech, 1 German, and 2 Caucasian individuals) with Monogenic Diabetes (PMID: 27106716, 22773699, 24918535, 20337973; DOI: 10.2337/db18-1509-P), and has been identified in 0.002893% (1/34564) of Latino chromosomes and 0.0008805% (1/113574) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs759072800). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 211073). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The number of missense variants reported in GCK in the general population is lower than expected, suggesting there is little benign variation in this gene and slightly increasing the possibility that a missense variant in this gene may not be tolerated. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4_Moderate, PM2_Supporting, PP2, PP3 (Richards 2015).	NA	NA	chr7-44151069-C-T
7-44191932-C-T	MODY	Review	GCK	NA	NA	NA	NA	vus		18	1	Uncertain significance - insufficient evidence: BS3_supporting	NA	NA	chr7-44152333-C-T
7-44192901-T-C	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3. Absent: 0.003266% (1/30616) South Asian chromosomes, but the individual in gnomAD was from the 52K dataset. Synonymous variant that is predicted to impact splicing, nt is somewhat conserved	NA	NA	NA
7-44192905-C-T	MODY	Review	GCK	NA	NA	NA	NA	vus		NA	6	Uncertain significance - insufficient evidence: BS1, PP3. 0.003879% (5/128887) of European (non-Finnish) chromosomes: 0.004655% (6/128888) on gnomAD but 1 is from 52K dataset. REVEL=0.983; very well conserved	NA	NA	chr7-44153306-C-T
7-44193001-C-T	MODY	Review	GCK	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2. Absent: 0.003266% (1/30616) of South Asian chromosomes, but the 1 het was in the 52K dataset	NA	NA	NA
7-44189396-G-GT	MODY	LOF	GCK	NA	NA	NA	NA	likely_not_lof	low pext  lots of ucsc tracks 	NA	1	NA	NA	NA	chr7-44149797-G-GT
7-44189591-G-A	MODY	LOF	GCK	16133	31172	1-Oct-18	Pathogenic	likely_not_lof	5 ucsc tracks  low pext	NA	1	NA	NA	NA	chr7-44149992-G-A
7-44185707-C-A	MODY	LOF	GCK	NA	NA	NA	NA	not_lof	Transcript error - minority of transcripts and weak conservation	3	NA	NA	NA	NA	NA
7-44197686-G-A	MODY	LOF	GCK	NA	NA	NA	NA	not_lof	Transcript error - minority of transcripts and weak conservation	1	NA	NA	NA	NA	NA
12-121426701-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	pathogenic		1	NA	PS4, PM2, PM1, PP3, PP1, PS3_supporting. at least 15 probands with variant and MODY (PMID: 24323243, 12442280, 22060211, 17937063, 18838325, 11315851, 9032114, 9287053, 18003757). at least 15 probands with variant and MODY (PMID: 24323243, 12442280, 22060211, 17937063, 18838325, 11315851, 9032114, 9287053, 18003757). variant found in DNA-binding region with highly deleterious and destabilizing effects, variant in exposed region and interacts with DNA, could affect protein function, reduction in hydrophobicity of mutant complex (PMID: 28410371). revel = 0.985 and well conserved. variant segregates with 4 individuals within 2 families (PMID: 11315851, 9032114). transcriptional activity 35% for variant protein, DNA binding 58% and Nuclear localization 59%, decrease in normalized luciferase activity compared to WT (PMID: 27899486)	Pathogenic	PS4, PP1_strong (6 meioses from 3 families in 9032114, 11315851), PS3_mod (only TA below 40%), PM1, PM2 (0.0008% in ENF, no other subpop), PP3 *didn't assess PP4	NA
12-121426835-C-T	MODY	ClinVar	HNF1A	372380	360075	6-Apr-16	NA	pathogenic	The p.Gln176Ter variant in HNF1A has been reported in 1 Southern Chinese family with maturity-onset diabetes of the young type 3 (MODY3) and has been identified in 0.0008856% (1/112922) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754728827). This variant has also been reported in ClinVar (VariationID: 372380) as pathogenic by GeneDx. In vitro functional studies in HeLa cells transfected with the variant demonstrating null expression and transactivation activities similar to those of an empty vector alone provide some evidence that the p.Gln176Ter variant may impact protein function  (PMID: 12107757). However, these types of assays may not accurately represent biological function. This nonsense variant leads to a premature termination codon at position 576, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the HNF1A gene is an established disease mechanism in MODY3. In summary, this variant meets criteria to be classified as pathogenic for MODY3 in an autosomal dominant manner based on the prediction that it will cause loss of function of the HNF1A gene, low frequency of the variant in the general population, and in vitro functional studies. ACMG/AMP Criteria applied: PVS1, PM2, PS3_moderate (Richards 2015).	NA	1	The p.Gln176Ter variant in HNF1A has been reported in 1 Southern Chinese family with maturity-onset diabetes of the young type 3 (MODY3) and has been identified in 0.0008856% (1/112922) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754728827). This variant has also been reported in ClinVar (VariationID: 372380) as pathogenic by GeneDx. In vitro functional studies in HeLa cells transfected with the variant demonstrating null expression and transactivation activities similar to those of an empty vector alone provide some evidence that the p.Gln176Ter variant may impact protein function  (PMID: 12107757). However, these types of assays may not accurately represent biological function. This nonsense variant leads to a premature termination codon at position 576, which is predicted to lead to a truncated or absent protein. Heterozygous loss of function of the HNF1A gene is an established disease mechanism in MODY3. In summary, this variant meets criteria to be classified as pathogenic for MODY3 in an autosomal dominant manner based on the prediction that it will cause loss of function of the HNF1A gene, low frequency of the variant in the general population, and in vitro functional studies. ACMG/AMP Criteria applied: PVS1, PM2, PS3_moderate (Richards 2015).	Pathogenic	PVS1, PS4, PS3_mod, PM2, PP1_strong, PP4_mod (6/25/19)	chr12-120989032-C-T
12-121431481-C-T	MODY	ClinVar	HNF1A	420064	408541	13-Mar-17	Pathogenic	pathogenic	High Confidence Lab	1	NA	Used HC lab assessment	Pathogenic	PVS1, PM2, PS4, PP4_mod, PP1_strong (7/23/19)	NA
12-121432065-G-A	MODY	ClinVar	HNF1A	449403	444937	14-Aug-17	Pathogenic	pathogenic	Used HC lab assessment	1	NA	Used HC lab assessment	Pathogenic	PM1 (dimerization domain), PS3 (abnl TA and localiztion; increased DNA binding PMID:26853433), PS4_mod (PMID: 12488961, 26997508, 26853433, 29758564, 17937063), PP4_mod (75%: 36 yo female dx 18, BMI 24.5, tx SU, neg AB, father affected: 26997508), PP1 (26997508: proband, daughter, father, sister = 3 meioses), PM5 (p.R271G, PMIDs: 12488961, 12050210, 17573900, and 18003757 and p.R271W, PMID: 12488961, 12574234, 15928245 and many others), PM2? (Absent ENF 1 copy in EA and 1 copy in SA), PP3 (REVEL 0.945),	NA
12-121434371-C-A	MODY	Review	HNF1A	NA	NA	NA	NA	pathogenic		4	NA	PP1_strong, PM1, PM5, PP3, PS4_supporting. variant segregates with 9 relatives from 3 families (PMID: 30293189, 21683639, 26479152). Moderate Residue described as mutation hotspot that has most mutations in the gene (PMID: 23348805, 16917892). p.Pro379Arg is likely path without PM5 (PMID: 23348805, 16917892, 29666556, 15657605) p.Pro379His is likely path without PM5 (PMID: 23348805, 16917892, 15883474). p.Pro379Ser is a VUS (VariationID: 30181854, 16917892, 23348805). p.Pro379Ala is a VUS. REVEL=0.967; very well conserved	Likely Pathogenic	PP1_strong, PS4_mod (three independent occurances; Colclough review says 7 families, unpublished data not sure of overlap btw literature- need to check), PM5 (Arg, His, Ala, Ser), PP3 (REVEL 0.967); Not PM2, PM1. Didn't assess PP4- would be Path w it	NA
12-121435363-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	pathogenic		NA	1	PVS1, PM2, PS3_moderate. Nonsense variant this is expected to undergo NMD, exon is present in a biologically relevant transcript. Absent	Pathogenic	PVS1, PS3 (PMID: 11162430: decreased TA and localization;  conf in 27899486), PM2	chr12-120997560-C-T
12-121437065-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	pathogenic		NA	1	PP1_strong, PM2, PS4_moderate, PP3, PM1_supporting. 0.0008841% (1/113114) of European (non-Finnish) chromosomes. Variant is predicted to affect splicing, nt is somewhat conserved. Sujjitjoon, 2008: Variant falls within transactivation domain of HNF1A, as does exon 7, which the variant is expected to cause skipping of.	Pathogenic	PVS1_strong (PMID: 12378390 shows variant causes exon 7 skipping and use of cryptic splice site), PS4 (PMID: 18338076, 12378390 (2 families), 12107757, 21683639 (Dublin- likely overlap w other reviews), 18003757 (6 occurrances), 23348805 (Colclough review- 15 families), PM2 (0.0000088 in ENF). Didn't assess PP4 (KM 7/29/19)	chr12-120999262-G-A
12-121432001-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	likely pathogenic		1	NA	PVS1, PM2. predicted to undergo NMD and variant present in biologically relevant transcript (not most expressed in mean but well expressed in pancreas). 0.0009% (1/112846) of European (non-Finnish) chromosomes. This individual is from our callset.	Pathogenic	PVS1, PM2 (0.0000089 in ENF), PP4 (son in PMID: 12442280, dx 23 tx diet- assume BMI 30, HbA1c 10- 45.4% chance, HbA1c 8- 62.4% chance, HbA1C 6- 75.5% chance)	NA
12-121432080-C-A	MODY	ClinVar	HNF1A	14945	29984	7-Jul-17	Likely pathogenic	likely pathogenic	High Confidence Lab	2	NA	Used HC lab assessment	Likely Pathogenic	PS4, PM1, PP3, PP4_mod (6/25/19)	NA
12-121426835-C-T	MODY	LOF	HNF1A	372380	360075	6-Apr-16	NA	lof	reads look good  pext 0.58  conservation good  majority of transcripts, splice site remains in tact (alamut)	NA	1	NA	NA	NA	chr12-120989032-C-T
12-121431481-C-T	MODY	LOF	HNF1A	420064	408541	13-Mar-17	Pathogenic	lof		1	NA	NA	NA	NA	NA
12-121432001-C-T	MODY	LOF	HNF1A	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
12-121434475-CA-C	MODY	LOF	HNF1A	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr12-120996672-CA-C
12-121435363-C-T	MODY	LOF	HNF1A	NA	NA	NA	NA	lof		NA	1	NA	NA	NA	chr12-120997560-C-T
12-121435443-CAT-C	MODY	LOF	HNF1A	NA	NA	NA	NA	likely_lof	doesn't kill all transcripts, but does kill the longer ones	1	NA	NA	NA	NA	NA
12-121435450-CAGCTGCAG-C	MODY	LOF	HNF1A	NA	NA	NA	NA	likely_lof	overprinting	NA	1	NA	NA	NA	chr12-120997647-CAGCTGCAG-C
12-121416600-C-T	MODY	ClinVar	HNF1A	435422	429373	13-Feb-15	NA	vus	Uncertain significance - insufficient evidence: The p.Thr10Met variant in HNF1A has been reported in at least 3 individuals with Monogenic Diabetes (PMID: 16917892, 18003757, 28938416), and has been identified in 0.01290% (2/15504) of African chromosomes, 0.005794% (2/34520) of Latino chromosomes, and 0.005473% (1/18270) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs774637975). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Thr10Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015).	5	2	Uncertain significance - insufficient evidence: The p.Thr10Met variant in HNF1A has been reported in at least 3 individuals with Monogenic Diabetes (PMID: 16917892, 18003757, 28938416), and has been identified in 0.01290% (2/15504) of African chromosomes, 0.005794% (2/34520) of Latino chromosomes, and 0.005473% (1/18270) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs774637975). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Thr10Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015).	NA	NA	chr12-120978797-C-T
12-121416621-T-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: BS1, PP3. 0.006503% (1/15378) of European (non-Finnish) chromosomes. REVEL=0.959; AA is completely conserved	NA	NA	chr12-120978818-T-A
12-121416710-G-C	MODY	Review	HNF1A	NA	NA	NA	NA	vus		2	3	Uncertain significance - insufficient evidence: PM2, BP4. 3 het in gnomad (1 Other) that are also in our dataset. 0.004% (1/24066) of African chromosomes and 0.0008% (1/123988) of European (non-Finnish) chromosomes. revel = 0.572 but opossum, wallaby, and Tasmanian devil have Arg at this position	NA	NA	chr12-120978907-G-C
12-121426649-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	2	Uncertain significance - insufficient evidence: BS1, PP3. 0.01% (3/30610) of South Asian chromosomes. One of these is in the dataset making the frequency 0.007% (2/30609) of South Asian chromosomes. revel = 0.952 and well conserved	NA	NA	chr12-120988846-C-T
12-121426652-G-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: PM2, PP3. Absent from gnomAD. REVEL=0.902; well conserved.	NA	NA	chr12-120988849-G-T
12-121426776-C-T	MODY	ClinVar	HNF1A	36822	45483	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.Thr156Met variant in HNF1A has been reported in one individual with Monogenic Diabetes in ClinVar (Variation ID: 36822), and has been identified in 0.01960% (6/30616) of South Asian chromosomes and 0.01129% (4/35434) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs150513055). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36822). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Thr156Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	6	1	Uncertain significance - insufficient evidence: The p.Thr156Met variant in HNF1A has been reported in one individual with Monogenic Diabetes in ClinVar (Variation ID: 36822), and has been identified in 0.01960% (6/30616) of South Asian chromosomes and 0.01129% (4/35434) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs150513055). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36822). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Thr156Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	chr12-120988973-C-T
12-121426790-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		2	3	Uncertain significance - conflicting evidence: BA1, PP3. 0.02% (20/113638) of European (non-Finnish) chromosomes, 0.007% (2/30616) of South Asian chromosomes, and 0.003% (1/34584) of Latino chromosomes. Three are in our study cohort. reve; = 0.931 and well conserved	NA	NA	chr12-120988987-G-A
12-121426812-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: BS1, PP3. 0.007% (2/30614) of South Asian chromosomes and 0.004% (5/113442) of European (non-Finnish) chromosomes. Two individuals are from our callset. revel = 0.886 and well conserved in mammals.	NA	NA	NA
12-121431499-G-C	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2, PP3, PS3_supporting, PM1_supporting. 0.003% (1/30604) of South Asian chromosomes. This person was in our callset. revel = 0.816 and well conserved	NA	NA	NA
12-121432115-G-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - conflicting evidence: BA1, PP3. 0.03017% (3/9944) of Ashkenazi Jewish individuals and 0.01057% (13/122942) of European (non-Finnish) individuals. REVEL=0.872; conserved.	NA	NA	chr12-120994312-G-T
12-121432119-C-G	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2. 0.003% (1/33344) of Latino chromosomes. Individual is from our callset.	NA	NA	NA
12-121432124-C-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	1	Uncertain significance - insufficient evidence: PS3_supporting, PS4_supporting.	NA	NA	chr12-120994321-C-A
12-121432125-C-G	MODY	ClinVar	HNF1A	36833	45494	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.Pro291Arg variant in HNF1A has been reported in at least one individual with Monogenic Diabetes in ClinVar (Variation ID: 36833), and has been identified in 0.03450% (8/23188) of African chromosomes and 0.0008106% (1/123362) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922606). This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36833). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. Another variant at the same position, p.Pro291Ser, has been reported benign in ClinVar (Variation ID: 447505). In summary, the clinical significance of the p.Pro291Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015).	4	1	Uncertain significance - insufficient evidence: The p.Pro291Arg variant in HNF1A has been reported in at least one individual with Monogenic Diabetes in ClinVar (Variation ID: 36833), and has been identified in 0.03450% (8/23188) of African chromosomes and 0.0008106% (1/123362) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922606). This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36833). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. Another variant at the same position, p.Pro291Ser, has been reported benign in ClinVar (Variation ID: 447505). In summary, the clinical significance of the p.Pro291Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015).	NA	NA	chr12-120994322-C-G
12-121432185-C-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		2	NA	Uncertain significance - insufficient evidence: PM2, PS4_supporting. 0.01% (2/16140) of East Asian chromosomes. These individuals are both from study cohort.	NA	NA	NA
12-121434071-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: BS1, PP3. 0.005014% (1/19946) of East Asian chromosomes, 0.003266% (1/30616) of South Asian chromosomes, and 0.001549% (2/129116) of European (non-Finnish) chromosomes. REVEL=0.856; well conserved.	NA	NA	chr12-120996268-G-A
12-121434170-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		5	7	Uncertain significance - insufficient evidence: BS1, PS4_supporting. 0.02% (6/35440) of Latino chromosomes and 0.009% (11/129110) of European (non-Finnish) chromosomes. 5 are in our cohort. at least 5 probands with MODY and variant (PMID: 27913849, 11058894, 29207974, 18003757)	NA	NA	chr12-120996367-C-T
12-121434371-C-G	MODY	ClinVar	HNF1A	431970	425956	31-Oct-18	Likely pathogenic	vus	Reassessed because of high AC, Adding BA1 changed variant to VUS. Also removed PS3 evidence showing that the variant led to increased bile acid synthesis. Uncertain significance - conflicting evidence: The p.Pro379Ala variant in HNF1A has been reported in 8 individuals with maturity-onset diabetes of the young type 3 (PMID: 19754856, 29207974, 23607861, 30202817, 30155490, 2176128) and has been Identified in 0.07914% (28/35382) of Latino chromosomes, and at lower frequencies in other populations, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754729248). This variant has also been reported in ClinVar (VariationID: 431970) as likely pathogenic by GeneDx and as pathogenic by Fulgent Genetics. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Pro379Ala have been reported in association with disease in the literature, suggesting that this variant is in a mutational hot spot and supports pathogenicity (PMID: 23348805, 16917892). Three additional likely pathogenic variants, resulting in a different amino acid change at the same position, p.Pro379Thr, p.Pro379Arg, and p.Pro379His, have been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 23348805, 16917892, 29666556, 15657605, 15883474, 30293189, 21683639, 26479152, 28012402).  In summary the clinical significance of the p.Pro379Ala variant is uncertain. ACMG/AMP Criteria applied: BA1, PS4_moderate, PM1, PM5, PP3,  (Richards 2015).	21	12	Reassessed because of high AC, Adding BA1 changed variant to VUS. Also removed PS3 evidence showing that the variant led to increased bile acid synthesis. Uncertain significance - conflicting evidence: The p.Pro379Ala variant in HNF1A has been reported in 8 individuals with maturity-onset diabetes of the young type 3 (PMID: 19754856, 29207974, 23607861, 30202817, 30155490, 2176128) and has been Identified in 0.07914% (28/35382) of Latino chromosomes, and at lower frequencies in other populations, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs754729248). This variant has also been reported in ClinVar (VariationID: 431970) as likely pathogenic by GeneDx and as pathogenic by Fulgent Genetics. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Multiple variants in the same region as p.Pro379Ala have been reported in association with disease in the literature, suggesting that this variant is in a mutational hot spot and supports pathogenicity (PMID: 23348805, 16917892). Three additional likely pathogenic variants, resulting in a different amino acid change at the same position, p.Pro379Thr, p.Pro379Arg, and p.Pro379His, have been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 23348805, 16917892, 29666556, 15657605, 15883474, 30293189, 21683639, 26479152, 28012402).  In summary the clinical significance of the p.Pro379Ala variant is uncertain. ACMG/AMP Criteria applied: BA1, PS4_moderate, PM1, PM5, PP3,  (Richards 2015).	NA	NA	chr12-120996568-C-G
12-121434458-C-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	NA	NA	NA	NA	NA
12-121434471-T-C	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	2	Uncertain significance - insufficient evidence: PM2, PP3. 0.0009% (1/113578) of European (non-Finnish) chromosomes. This individual is from study cohort. revel = 0.963 and well conserved.	NA	NA	chr12-120996668-T-C
12-121435367-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: BS1, PS4_supporting. 0.008697% (3/34496) of Latino chromosomes and 0.0008865% (1/112804) of European (non-Finnish) chromosomes	NA	NA	chr12-120997564-C-T
12-121435391-C-T	MODY	ClinVar	HNF1A	36801	45462	18-Aug-11	NA	vus		2	NA	Uncertain significance - insufficient evidence: The p.Pro475Leu variant in HNF1A has been reported in at least 2 individuals (including 1 Thai individual) with Monogenic Diabetes (PMID: 18811724, 23348805), and has been identified in 0.09954% (10/10046) of Ashkenazi Jewish chromosomes and 0.002659% (3/112840) European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922580). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and as a VUS in the literature (Variation ID: 36801; PMID: 27080136). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Pro475Leu variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3, PS4_Supporting (Richards 2015).	NA	NA	NA
12-121435461-C-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		2	1	Uncertain significance - insufficient evidence: PM2. 0.006% (2/33864) of Latino chromosomes and 0.0009% (1/108942) of European (non-Finnish) chromosomes. These 3 individuals are from study cohort.	NA	NA	chr12-120997658-C-A
12-121435465-C-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - conflicting evidence: BA1, PP3. 0.01147% (1/8716) of African chromosomes and 0.006482% (1/15428) of European (non-Finnish) chromosomes. REVEL=0.8; very well conserved, not predicted to impact splicing.	NA	NA	chr12-120997662-C-A
12-121435468-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence; PP3. revel = 0.703 and well conserved with 2 birds having Thr at this position	NA	NA	NA
12-121437106-A-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	NA	Uncertain significance - insufficient evidence: PM2. 0.002% (2/113456) of European (non-Finnish). One of these is from study cohort.	NA	NA	NA
12-121437142-A-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		NA	6	Uncertain significance - insufficient evidence: BS1, PP3. 0.008531% (11/128938) of European (non-Finnish) chromosomes. REVEL=0.826; well conserved.	NA	NA	chr12-120999339-A-T
12-121437145-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	2	Uncertain significance - insufficient evidence: BS1, PP3. 0.005% (1/18390) of East Asian chromosomes and 0.004% (4/113566) of European (non-Finnish) chromosomes. revel = 0.805 and well conserved	NA	NA	chr12-120999342-G-A
12-121437152-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	1	Uncertain significance - insufficient evidence: PM2. 0.002% (2/128978) of European (non-Finnish) chromosomes. One of these individuals is from study cohort.	NA	NA	chr12-120999349-C-T
12-121437325-C-T	MODY	ClinVar	HNF1A	36808	45469	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.Leu555Phe variant in HNF1A has been reported in 1 individual with maturity-onset diabetes of the young type 3 (PMID: 18003757) and has been identified in 0.001797% (2/111302) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922587). This variant has also been reported in ClinVar (VariationID: 36808) as likely pathogenic by Integrated Genetics. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. One affected individual with this variant have an alternative molecular basis for maturity-onset diabetes of the young, suggesting that this variant may not be pathogenic (PMID: 22341299). In summary, the clinical significance of the p.Leu555Phe variant is uncertain. ACMG/AMP Criteria applied: PM2, BP5 (Richards 2015).	NA	3	Uncertain significance - insufficient evidence: The p.Leu555Phe variant in HNF1A has been reported in 1 individual with maturity-onset diabetes of the young type 3 (PMID: 18003757) and has been identified in 0.001797% (2/111302) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922587). This variant has also been reported in ClinVar (VariationID: 36808) as likely pathogenic by Integrated Genetics. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. One affected individual with this variant have an alternative molecular basis for maturity-onset diabetes of the young, suggesting that this variant may not be pathogenic (PMID: 22341299). In summary, the clinical significance of the p.Leu555Phe variant is uncertain. ACMG/AMP Criteria applied: PM2, BP5 (Richards 2015).	NA	NA	chr12-120999522-C-T
12-121437365-C-T	MODY	Review	HNF1A	NA	NA	NA	NA	vus		1	1	Uncertain significance - insufficient evidence: PS4. variant found in 1 MODY patient ( PMID: 23348805).	NA	NA	chr12-120999562-C-T
12-121437407-A-G	MODY	ClinVar	HNF1A	36811	45472	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.His582Arg variant in HNF1A has been reported in at least 2 individuals (including 1 Norwegian individual) with Monogenic Diabetes (PMID: 23624530, 27913849, 23348805), and has been identified in 0.01166% (4/34300) of Latino chromosomes, 0.006571% (1/15218) of African chromosomes, and 0.005645% (6/106288) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922589). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and as a VUS in the literature (Variation ID: 36811; PMID: 27080136). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.His582Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015).	3	1	Uncertain significance - insufficient evidence: The p.His582Arg variant in HNF1A has been reported in at least 2 individuals (including 1 Norwegian individual) with Monogenic Diabetes (PMID: 23624530, 27913849, 23348805), and has been identified in 0.01166% (4/34300) of Latino chromosomes, 0.006571% (1/15218) of African chromosomes, and 0.005645% (6/106288) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922589). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and as a VUS in the literature (Variation ID: 36811; PMID: 27080136). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.His582Arg variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PS4_Supporting (Richards 2015).	NA	NA	chr12-120999604-A-G
12-121438954-G-A	MODY	Review	HNF1A	NA	NA	NA	NA	vus		2	NA	Uncertain significance - insufficient evidence: PM2	NA	NA	NA
12-121437283-C-T	MODY	LOF	HNF1A	NA	NA	NA	NA	likely_not_lof	pext=0.1  partial exon conservation	NA	1	NA	NA	NA	chr12-120999480-C-T
12-121438900-TC-T	MODY	LOF	HNF1A	NA	NA	NA	NA	likely_not_lof	reads look good  in majority of transcripts  good conservation  last exon though	NA	1	NA	NA	NA	chr12-121001097-TC-T
12-121416474-G-A	MODY	LOF	HNF1A	NA	NA	NA	NA	not_lof	minority of tx (only found in ensembl tx), strong met rescue, overhang exon?, weak conservation, low pext compared to rest of gene - 5	2	NA	NA	NA	NA	NA
12-121431383-C-T	MODY	LOF	HNF1A	NA	NA	NA	NA	not_lof	Only in one transcript  low pext  NON_CAN_SPLICE	NA	1	NA	NA	NA	chr12-120993580-C-T
12-121431384-C-A	MODY	LOF	HNF1A	NA	NA	NA	NA	not_lof	Only in one transcript  low pext  NON_CAN_SPLICE	NA	1	NA	NA	NA	chr12-120993581-C-A
12-121434406-G-A	MODY	LOF	HNF1A	NA	NA	NA	NA	not_lof	Only in a single transcript and also has a nagnag flag. pext 0	NA	1	NA	NA	NA	chr12-120996603-G-A
12-121435293-G-A	MODY	LOF	HNF1A	NA	NA	NA	NA	not_lof	no reads, rescue within 6bp, minotirty tx, similar pext to rest of gene (overall low), last exon - 5	1	NA	NA	NA	NA	NA
12-121432114-CG-C	MODY	ClinVar	HNF1A	435424	429378	23-Dec-16	NA	NA	Found in too many controls	5	NA	Found in too many controls	NA	NA	NA
12-121432114-CG-C	MODY	LOF	HNF1A	435424	429378	23-Dec-16	NA	NA	Genotyping error	5	NA	NA	NA	NA	NA
12-121432116-G-GC	MODY	LOF	HNF1A	NA	NA	NA	NA	NA	Genotyping error, Reads don't look good, bad AB, reads in gnomAD also look bad. Right at a homopolymer	5	7	NA	NA	NA	chr12-120994313-G-GC
12-121432117-G-GC	MODY	ClinVar	HNF1A	14927	29966	6-Nov-17	Pathogenic	NA	After reassessment High frequency in gnomAD (https://gnomad.broadinstitute.org/variant/12-121432117-G-GC). Variant is a frameshift (insertion of C) in a hompolymer. In gnomAD it failed random forest for exomes and genomes. It is described as path by multiple submitters in ClinVar. It reaches pathogenic, but reads in gnomAD and AMP T2D carriers look suspicious. Variant excluded in LoF curation as homopolymer error. The variant may well be real in some individuals, we can't trust the overall genotyping so this variant was excluded from the analysis.	15	NA	After reassessment High frequency in gnomAD (https://gnomad.broadinstitute.org/variant/12-121432117-G-GC). Variant is a frameshift (insertion of C) in a hompolymer. In gnomAD it failed random forest for exomes and genomes. It is described as path by multiple submitters in ClinVar. It reaches pathogenic, but reads in gnomAD and AMP T2D carriers look suspicious. Variant excluded in LoF curation as homopolymer error. The variant may well be real in some individuals, we can't trust the overall genotyping so this variant was excluded from the analysis.	NA	NA	NA
12-121432117-G-GC	MODY	LOF	HNF1A	14927	29966	6-Nov-17	Pathogenic	NA	Genotyping error	15	NA	NA	NA	NA	NA
12-121432117-G-GC	MODY	Review	HNF1A	14927	29966	6-Nov-17	Pathogenic	NA		15	NA	Would be considered pathogenic, but because of the poor genotyping quality at this site it is difficult to determine which individuals are actually carriers.	NA	NA	NA
17-36093806-G-A	MODY	LOF	HNF1B	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
17-36070609-C-T	MODY	ClinVar	HNF1B	379811	376001	17-Apr-17	NA	vus	Uncertain Significance - Insufficient Evidence: PP1, PM2; also VUS by high confidence lab (GeneDx and EGL) after Jan 2017	19	NA	Uncertain Significance - Insufficient Evidence: PP1, PM2; also VUS by high confidence lab (GeneDx and EGL) after Jan 2017	NA	NA	NA
17-36091625-G-A	MODY	ClinVar	HNF1B	36837	45498	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.His336Tyr variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 377055), and has been identified in 0.02611% (9/34468) of Latino chromosomes and 0.0008848% (1/113020) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs138986885). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36837). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.His336Tyr variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	3	5	Uncertain significance - insufficient evidence: The p.His336Tyr variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 377055), and has been identified in 0.02611% (9/34468) of Latino chromosomes and 0.0008848% (1/113020) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs138986885). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36837). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.His336Tyr variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	chr17-37731634-G-A
17-36091682-C-A	MODY	ClinVar	HNF1B	36854	45515	18-Aug-11	NA	vus		3	NA	Uncertain significance - insufficient evidence: The p.Ala317Ser variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 36854), and has been identified in 0.008674% (3/34588) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922492). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36854). In summary, the clinical significance of the p.Ala317Ser variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	NA
17-36099458-C-T	MODY	Review	HNF1B	NA	NA	NA	NA	vus		2	NA	Uncertain significance - insufficient evidence: PP3. revel = 0.707 and well conserved, no effect on splicing	NA	NA	NA
17-36099641-A-C	MODY	Review	HNF1B	NA	NA	NA	NA	vus		1	NA	Uncertain significance - conflicting evidence: PM2, BP7, BP4. 0.002% (2/102988) of European (non-Finnish) chromosomes. One individual is from study cohort. no effect on splicing and nucleotide is not well conserved. no effect on splicing.	NA	NA	NA
17-36104674-C-G	MODY	Review	HNF1B	NA	NA	NA	NA	vus		1	1	Uncertain significance - conflicting evidence: BA1, PP3. 0.04% (13/30610) of South Asian chromosomes. One of these individuals is from the study cohort. revel = 0.931 and well conserved	NA	NA	chr17-37744683-C-G
17-36104736-G-A	MODY	ClinVar	HNF1B	36840	45501	18-Aug-11	NA	vus		6	NA	Uncertain significance - insufficient evidence: The p.Pro47Leu variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 36840), and has been identified in 0.02024% (7/34580) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922483). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36840). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Pro47Leu variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	NA
17-36104769-G-A	MODY	Review	HNF1B	NA	NA	NA	NA	vus		18	1	Uncertain significance - conflicting evidence: BA1, PS3_supporting. 0.2% (36/19922) of East Asian chromosomes. Twenty of these individuals are from study cohort. potential GOF mechanism (PMID: 11845238)	NA	NA	chr17-37744778-G-A
17-36104776-G-A	MODY	Review	HNF1B	NA	NA	NA	NA	vus		5	1	Uncertain significance - conflicting evidence: PM2, BP7, BP4. 0.03% (8/30614, 1 HOM) of South Asian chromosomes. All of these individuals are from study cohort. no effect on splicing and nucleotide is not well conserved. no effect on splicing and nucleotide is not well conserved	NA	NA	chr17-37744785-G-A
17-36093697-T-A	MODY	Review	HNF1B	NA	NA	NA	NA	benign		2	NA	BA1. 0.03% (6/19950) of East Asian chromosomes. Three of these are from study cohort.	NA	NA	NA
17-36093699-A-G	MODY	Review	HNF1B	NA	NA	NA	NA	benign		NA	2	BA1. 0.01% (18/129182) of European (non-Finnish) chromosomes and 0.01% (1/10370) of Ashkenazi Jewish chromosomes. One of these individuals is from study cohort.	NA	NA	chr17-37733706-A-G
17-36093738-T-A	MODY	LOF	HNF1B	NA	NA	NA	NA	likely_not_lof	perfectly viable alternative splice sites nearby, used in other transcripts, Transcript error - minority of transcripts and not expressed	1	NA	NA	NA	NA	NA
17-36065024-G-A	MODY	LOF	HNF1B	NA	NA	NA	NA	not_lof	pext 0 PHYLOCSF_UNLIKELY_ORF LoF in the overprinted transcript	NA	5	NA	NA	NA	chr17-37705017-G-A
20-43052700-G-A	MODY	Review	HNF4A	NA	NA	NA	NA	likely pathogenic		1	NA	PM2, PS4_moderate, PM1, PP3, PM5_supporting, PS3_supporting, PP1. Absent: 0.0008974% (1/111436) of European (non-Finnish) chromosomes on gnomAD, but the 1 het is from 52K dataset. REVEL=0.919; VERY well conserved. p.Arg312Cys (VariationID: 447524) in same codon is LP on clinvar	Likely Pathogenic	PS4_Moderate (PMID:23348805 (Colclough review- 5 families), 27552834 (one family)), PM2 (0.000008974 in ENF), PM5 (R290C: PP1_Strong (27552834- 1 family, 8 individuals), PS4_Mod (5 families in Colclough review + 23348805), PM2, PP3), PP1 (3 meioses in PMID: 17407387), PP3 (REVEL 0.919),	NA
20-43042354-C-T	MODY	ClinVar	HNF4A	9212	24251	12-Dec-17	NA	vus	Uncertain Significance - Conflicting Evidence, Uncertain Significance - Conflicting Evidence: BS2, PP3; also VUS by high confidence lab (GeneDx). 	4	18	Uncertain Significance - Conflicting Evidence: BS2, PP3; also VUS by high confidence lab (GeneDx)	NA	NA	chr20-44413714-C-T
20-43042375-A-G	MODY	ClinVar	HNF4A	36349	45013	20-Mar-17	NA	vus	Uncertain significance - insufficient evidence: The p.Ser143Gly variant in HNF4A has been reported in 1 individual with Maturity-Onset Diabetes of the Young in ClinVar (Variation ID: 36349), and has been identified in 0.01145% (13/113552) of European (non-Finnish) chromosomes and 0.002894% (1/34554) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922472). This variant has also been reported in an individual without diabetes (PMID: 24097065). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 36349). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Ser143Gly variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	1	22	Uncertain significance - insufficient evidence: The p.Ser143Gly variant in HNF4A has been reported in 1 individual with Maturity-Onset Diabetes of the Young in ClinVar (Variation ID: 36349), and has been identified in 0.01145% (13/113552) of European (non-Finnish) chromosomes and 0.002894% (1/34554) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922472). This variant has also been reported in an individual without diabetes (PMID: 24097065). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 36349). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Ser143Gly variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	chr20-44413735-A-G
20-43042436-G-A	MODY	Review	HNF4A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: PP3, BP4. REVEL=0.539; VERY poorly conserved. REVEL=0.539; VERY poorly conserved.	NA	NA	chr20-44413796-G-A
20-43047071-C-A	MODY	Review	HNF4A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: PM2, PM1, PP3. Absent from gnomAD. REVEL=0.903; perfectly conserved.	NA	NA	chr20-44418431-C-A
20-43048458-G-C	MODY	ClinVar	HNF4A	36360	45024	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.Glu278Asp variant in HNF4A has been reported in one individual with suspected Maturity-Onset Diabetes of the Young (PMID: 26059258), and has been identified in 0.004005% (1/24968) of African chromosomes and 0.0007741% (1/129180) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922477). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and likely benign in the literature (Variation ID: 36360; PMID: 26059258). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Glu278Asp variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015).	2	6	Uncertain significance - insufficient evidence: The p.Glu278Asp variant in HNF4A has been reported in one individual with suspected Maturity-Onset Diabetes of the Young (PMID: 26059258), and has been identified in 0.004005% (1/24968) of African chromosomes and 0.0007741% (1/129180) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922477). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar and likely benign in the literature (Variation ID: 36360; PMID: 26059258). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the p.Glu278Asp variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting (Richards 2015).	NA	NA	chr20-44419818-G-C
20-43048481-A-G	MODY	Review	HNF4A	NA	NA	NA	NA	vus		NA	6	Uncertain significance - insufficient evidence: PP3. REVEL=0.95; very well conserved.	NA	NA	chr20-44419841-A-G
20-43052694-G-A	MODY	Review	HNF4A	NA	NA	NA	NA	vus		4	5	Uncertain significance - insufficient evidence: BS1. 0.009% (12/126714) of European (non-Finnish) chromosomes and others at lesser frequencies. Four individuals in gnomad are from study cohort.	NA	NA	chr20-44424054-G-A
20-43052757-G-T	MODY	Review	HNF4A	NA	NA	NA	NA	vus		NA	1	Uncertain significance - insufficient evidence: PM2, PP3. Absent from gnomAD. REVEL=0.834; very well conserved.	NA	NA	chr20-44424117-G-T
20-43052763-G-A	MODY	ClinVar	HNF4A	586023	577863	22-Nov-17	NA	vus	Uncertain significance - insufficient evidence: Variant has BS1 frequency 0.005% but only 1 het on gnomad--south asian population. If PM2 it is LP, if not it is VUS. The p.Arg333His variant in HNF4A has been reported in at least 3 individuals with maturity-onset diabetes of the young type 1 (MODY1) (PMID: 24947580, 25414397, 26059258) and has been Identified in 0.005451% (1/18346) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1375557127). In vitro functional studies demonstrating reduced relative activity in cells transfected with the variant provide some evidence that the p.Arg333His variant may slightly impact protein function (PMID: 23485969). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Arg333His variant is located in a region of HNF1A that is essential to ligand binding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 23485969). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: BS1, PM2, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015).	NA	1	Uncertain significance - insufficient evidence: Variant has BS1 frequency 0.005% but only 1 het on gnomad--south asian population. If PM2 it is LP, if not it is VUS. The p.Arg333His variant in HNF4A has been reported in at least 3 individuals with maturity-onset diabetes of the young type 1 (MODY1) (PMID: 24947580, 25414397, 26059258) and has been Identified in 0.005451% (1/18346) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1375557127). In vitro functional studies demonstrating reduced relative activity in cells transfected with the variant provide some evidence that the p.Arg333His variant may slightly impact protein function (PMID: 23485969). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Arg333His variant is located in a region of HNF1A that is essential to ligand binding and stability, suggesting that this variant is in a functional domain and slightly supports pathogenicity (PMID: 23485969). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: BS1, PM2, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015).	NA	NA	chr20-44424123-G-A
20-43053004-T-TG	MODY	LOF	HNF4A	NA	NA	NA	NA	not_lof	low pext	NA	1	NA	NA	NA	chr20-44424364-T-TG
20-43053010-AG-A	MODY	LOF	HNF4A	NA	NA	NA	NA	not_lof	low pext	NA	1	NA	NA	NA	chr20-44424370-AG-A
20-43057104-G-A	MODY	LOF	HNF4A	NA	NA	NA	NA	not_lof	Within the 50 penultimate BP	1	NA	NA	NA	NA	NA
13-28494457-GC-G	MODY	ClinVar	PDX1	21124	33976	25-Jan-17	NA	pathogenic	The p.Pro63Argfs variant in PDX1 has been reported in 9 individuals with maturity-onset diabetes of the young type 4 (MODY type 4), segregated with disease in those 9 affected relatives from 1 family (PMID: 20621032), and this variant has been identified in 0.002% (1/49632) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; rs193929377). This variant has also been reported in ClinVar as pathogenic (Variation ID: 21124). In vitro functional studies provide some evidence that the p.Pro63Argfs variant may slightly impact protein function (PMID:15001545). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the proteins amino acid sequence beginning at position 63 and leads to a premature termination codon 60 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the PDX1 gene is an established disease mechanism in MODY type 4. In summary, this variant meets criteria to be classified as pathogenic for MODY type 4 in an autosomal dominant manner based on the predicted impact of this loss of function variant and the strong segregation seen with this variant and MODY type 4. ACMG/AMP Criteria applied: PVS1, PP1_strong, PM2, PS3_supporting (Richards 2015).	NA	1	The p.Pro63Argfs variant in PDX1 has been reported in 9 individuals with maturity-onset diabetes of the young type 4 (MODY type 4), segregated with disease in those 9 affected relatives from 1 family (PMID: 20621032), and this variant has been identified in 0.002% (1/49632) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; rs193929377). This variant has also been reported in ClinVar as pathogenic (Variation ID: 21124). In vitro functional studies provide some evidence that the p.Pro63Argfs variant may slightly impact protein function (PMID:15001545). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the proteins amino acid sequence beginning at position 63 and leads to a premature termination codon 60 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the PDX1 gene is an established disease mechanism in MODY type 4. In summary, this variant meets criteria to be classified as pathogenic for MODY type 4 in an autosomal dominant manner based on the predicted impact of this loss of function variant and the strong segregation seen with this variant and MODY type 4. ACMG/AMP Criteria applied: PVS1, PP1_strong, PM2, PS3_supporting (Richards 2015).	Pathogenic	PVS1, PM2, (28436541(1 family, 2 early-onset DM pts, also 2 non-carriers late onsent DM pts),8988180 (1 family, complicated pedigree of this family is better shown in 20621032), hard to calculate PP1 since also NN DM pt exists), PS3_mod (8988180 showed mutant PDX1 is shortened by western blot, localiztion is abnormal compared to WT)	chr13-27920320-GC-G
13-28494677-G-A	MODY	LOF	PDX1	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
13-28494574-TC-T	MODY	LOF	PDX1	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
13-28494327-T-C	MODY	ClinVar	PDX1	8862	23901	10-Oct-16	NA	vus	Uncertain significance - insufficient evidence:  Variant seems to be somewhat damaging but with very low penetrance, also, maybe use BS1? Seems mostly associated with T2D than MODY. The p.Cys18Arg variant in PDX1 has been reported in at least 3 individuals with type 2 diabetes mellitus (PMID: 10545530, 27879214; DOI: 10.7324/JABB.2013.1205), and has been identified in 0.02173% (15/69030) of European (non-Finnish) chromosomes, 0.01066% (2/18762) of European (Finnish) chromosomes, and 0.003943% (1/25360) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852785). In vitro functional studies provide some evidence that the p.Cys18Arg variant may slightly impact protein function, resulting in moderately decreased binding activity to the insulin promoter and decreased transcription of insulin in response to hyperglycemia  (PMID: 30930126, 10545530). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Cys18Arg variant did not segregate with type 2 diabetes mellitus in 3 affected relatives of  individuals with the variant, suggesting that this variant is not pathogenic for type 2 diabetes mellitus (PMID: 10545530). The variant is located in a region of PDX1 that is important for protein binding, suggesting that this variant is in a functional domain and slighly supports pathogenicity (PMID: 27879214).  In summary, the clinical significance of the p.Cys18Arg variant is uncertain. ACMG/AMP Criteria applied: BS4, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015).	3	24	Uncertain significance - insufficient evidence:  Variant seems to be somewhat damaging but with very low penetrance, also, maybe use BS1? Seems mostly associated with T2D than MODY. The p.Cys18Arg variant in PDX1 has been reported in at least 3 individuals with type 2 diabetes mellitus (PMID: 10545530, 27879214; DOI: 10.7324/JABB.2013.1205), and has been identified in 0.02173% (15/69030) of European (non-Finnish) chromosomes, 0.01066% (2/18762) of European (Finnish) chromosomes, and 0.003943% (1/25360) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852785). In vitro functional studies provide some evidence that the p.Cys18Arg variant may slightly impact protein function, resulting in moderately decreased binding activity to the insulin promoter and decreased transcription of insulin in response to hyperglycemia  (PMID: 30930126, 10545530). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The p.Cys18Arg variant did not segregate with type 2 diabetes mellitus in 3 affected relatives of  individuals with the variant, suggesting that this variant is not pathogenic for type 2 diabetes mellitus (PMID: 10545530). The variant is located in a region of PDX1 that is important for protein binding, suggesting that this variant is in a functional domain and slighly supports pathogenicity (PMID: 27879214).  In summary, the clinical significance of the p.Cys18Arg variant is uncertain. ACMG/AMP Criteria applied: BS4, PP3, PS4_supporting, PS3_supporting, PM1_supporting (Richards 2015).	NA	NA	chr13-27920190-T-C
13-28494372-C-A	MODY	ClinVar	PDX1	36414	45077	10-Jun-16	NA	vus	Uncertain significance - conflicting evidence: The p.Pro33Thr variant in PDX1 has been reported in 1 individual with maturity-onset diabetes of the young type 4 (PMID: 16092045), but has been identified in 0.7% (164/22330) of South Asian chromosomes as well as other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs192902098). This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36414). In vitro functional studies provide some evidence that the p.Pro33Thr variant may impact protein function (PMID: 16092045, 30930126). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. ACMG/AMP Criteria applied: BA1, PS3_moderate, PP3 (Richards 2015).	77	140	Uncertain significance - conflicting evidence: The p.Pro33Thr variant in PDX1 has been reported in 1 individual with maturity-onset diabetes of the young type 4 (PMID: 16092045), but has been identified in 0.7% (164/22330) of South Asian chromosomes as well as other populations at lesser frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs192902098). This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36414). In vitro functional studies provide some evidence that the p.Pro33Thr variant may impact protein function (PMID: 16092045, 30930126). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. ACMG/AMP Criteria applied: BA1, PS3_moderate, PP3 (Richards 2015).	NA	NA	chr13-27920235-C-A
13-28494501-G-A	MODY	ClinVar	PDX1	8859	23898	5-Feb-18	NA	benign	The p.Asp76Asn variant in PDX1 (sometimes called IPF1) has been reported in at least 32 individuals with Maturity-Onset Diabetes of the Young (PMID: 15277425, 10545531, 10545530, 17592437), and has been identified in 0.4909% (336/68440) of European (non-Finnish) chromosomes, including 2 homozygotes, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852783). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. However, this variant does not segregate with disease in many families, including sibling pairs (PMID: 10545531, 15277425). This variant has also been reported as a benign variant, likely benign variant, VUS, likely pathogenic variant, and risk factor for diabetes in ClinVar (Variation ID: 8859). In vitro functional studies provide some evidence that the p.Asp76Asn variant may slightly impact protein function, but this evidence is not conclusive (PMID: 10545531). These types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for Maturity-Onset Diabetes of the Young in an autosomal dominant manner based on a higher than expected frequency in control cohorts and nonsegregation with MODY. ACMG/AMP Criteria applied: BS2, BS4, BP4 (Richards 2015).	91	485	The p.Asp76Asn variant in PDX1 (sometimes called IPF1) has been reported in at least 32 individuals with Maturity-Onset Diabetes of the Young (PMID: 15277425, 10545531, 10545530, 17592437), and has been identified in 0.4909% (336/68440) of European (non-Finnish) chromosomes, including 2 homozygotes, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852783). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. However, this variant does not segregate with disease in many families, including sibling pairs (PMID: 10545531, 15277425). This variant has also been reported as a benign variant, likely benign variant, VUS, likely pathogenic variant, and risk factor for diabetes in ClinVar (Variation ID: 8859). In vitro functional studies provide some evidence that the p.Asp76Asn variant may slightly impact protein function, but this evidence is not conclusive (PMID: 10545531). These types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for Maturity-Onset Diabetes of the Young in an autosomal dominant manner based on a higher than expected frequency in control cohorts and nonsegregation with MODY. ACMG/AMP Criteria applied: BS2, BS4, BP4 (Richards 2015).	NA	NA	chr13-27920364-G-A
13-28498711-C-T	MODY	ClinVar	PDX1	36411	45074	28-Mar-16	NA	benign	The p.Pro242Leu variant in PDX1 has been reported in at least 1 Asian individual with maturity-onset diabetes of the young type 4 (PMID: 27420379), and has been identified in 0.2% (124/58140) of European (non-Finnish) chromosomes and multiple other populations at lower frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922358). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36411). Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for MODY type 4 in an autosomal dominant manner based on computational tool predictions and the frequency of this variant in multiple populations. ACMG/AMP Criteria applied: BP4, BA1 (Richards 2015).	21	126	The p.Pro242Leu variant in PDX1 has been reported in at least 1 Asian individual with maturity-onset diabetes of the young type 4 (PMID: 27420379), and has been identified in 0.2% (124/58140) of European (non-Finnish) chromosomes and multiple other populations at lower frequencies by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922358). This variant has been seen in the general population at a frequency high enough to rule out a pathogenic role. This variant has also been reported in ClinVar as having conflicting interpretations of pathogenicity (Variation ID: 36411). Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, this variant meets criteria to be classified as benign for MODY type 4 in an autosomal dominant manner based on computational tool predictions and the frequency of this variant in multiple populations. ACMG/AMP Criteria applied: BP4, BA1 (Richards 2015).	NA	NA	chr13-27924574-C-T
13-28494457-GC-G	MODY	LOF	PDX1	21124	33976	25-Jan-17	NA	likely_not_lof		NA	1	NA	NA	NA	chr13-27920320-GC-G
13-28498683-G-T	MODY	LOF	PDX1	NA	NA	NA	NA	not_lof	strand bias, low read depth, last exon, partial exon conservation, disrupts <25% sequence, high pext - 4	2	NA	NA	NA	NA	NA
11-17417461-C-T	MODY Extended	ClinVar	ABCC8	585346	577178	28-Sep-17	NA	likely pathogenic		1	NA	The p.Arg1379His (sometimes called p.Arg1380His) variant in ABCC8 has been reported in 12 individuals with Monogenic Diabetes and segregated with disease in 5 affected relatives from 2 families (PMID: 22210575, 23093687, 27271189, 21989597, 19342262, 17446535, 17389331; DOI: 10.1016/j.clinph.2015.04.103). Data from large population studies is insufficient to assess the frequency of this variant. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 585346). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Three additional variants, each with a different amino acid change at the same position, (p.Arg1379Leu, p.Arg1379Ser, and p.Arg1379Cys), have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 18025464; Variation ID: 9105, 35614, 35615). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM5, PP1_Moderate, PP3, PS4_moderate (Richards 2015).	Pathogenic	PP1_Moderate, PP3, PS4 (29207974(1), 17389331(1), 31110826(1), 27271189(1), 26438614(1), 22210575(1), 23093687(1 family, two pts),17446535(1)), PM2 (absent in gnomAD, failed QC), PM5(R1379L: Likely path: PP3, PM1, PM2, PS3_mod(18025464 enhanced ATPase activity at NBD2), ?PS4_mod(18025408 (2)), even Path already with PP1_sup. 	NA
11-17417462-G-T	MODY Extended	ClinVar	ABCC8	35614	44279	9-May-18	NA	vus		2	NA	The p.Arg1379Ser (sometimes called p.Arg1380Ser) variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes (PMID: 25555642), and has been identified in 0.009857% (3/30434) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852673). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and as a likely pathogenic variant in ClinVar (Variation ID: 35614). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Three additional variants, each with a different amino acid change at the same position, (p.Arg1379Leu, p.Arg1379His, and p.Arg1379Cys), have been reported in association with disease in ClinVar or curated as a likely pathogenic variant or variant of uncertain significance by our study, supporting that a change at this position may not be tolerated (Variation ID: 35615). In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM5, PM2_Supporting, PP3 (Richards 2015).	NA	NA	NA
11-17426099-C-T	MODY Extended	ClinVar	ABCC8	35609	44274	1-Jan-17	NA	vus	Uncertain significance - insufficient evidence: The p.Val1173Met variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 35609), and has been identified in 0.003098% (4/129110) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs141322087). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 35609). Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Val1173Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, BP4 (Richards 2015).	NA	3	Uncertain significance - insufficient evidence: The p.Val1173Met variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 35609), and has been identified in 0.003098% (4/129110) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs141322087). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 35609). Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Val1173Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, BP4 (Richards 2015).	NA	NA	chr11-17404552-C-T
11-17482160-C-T	MODY Extended	ClinVar	ABCC8	35624	44289	9-Nov-17	NA	vus		1	NA	Uncertain significance - insufficient evidence: The p.Gly296Arg variant in ABCC8 has been reported in 1 Chinese and 1 Pakistan individuals, in the heterozygous or compound heterozygous state, with Monogenic Diabetes (PMID: 22562119, 26839896), and has been identified in 0.004013% (1/24920) of African chromosomes, 0.003267% (1/30610) of South Asian chromosomes, and 0.001555% (2/128636) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs148529020). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 35624). In vitro functional studies provide some evidence that the p.Gly296Arg variant may slightly increase protein activity (PMID: 22562119). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. This variant is located in the L0 domain, which has been associated with changes in the K-ATP channel of the protein and diabetes (PMID: 22562119). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3, PS3_Supporting, PM1_Supporting (Richards 2015).	NA	NA	NA
11-17434263-G-A	MODY Extended	ClinVar	ABCC8	188915	186816	31-Oct-18	NA	NA	Variant assocaited only with Hyperinsulemic hyperglycemia in the literature	12	1	Variant assocaited only with Hyperinsulemic hyperglycemia in the literature	NA	NA	chr11-17412716-G-A
11-17409079-G-A	MODY Extended	ClinVar	ABCC8,KCNJ11	551187	546193	21-Mar-17	NA	NA	Variant assocaited only with CHI in the literature	NA	1	Variant assocaited only with CHI in the literature	NA	NA	chr11-17387532-G-A
9-135947060-CT-C	MODY Extended	ClinVar	CEL	290893	275130	26-Aug-16	NA	vus		18	NA	Uncertain significance - insufficient evidence: The p.Val728Cysfs variant in CEL has been reported in 1 Northern European individual with Maturity-Onset Diabetes of the Young (PMID: 29207974), but was absent from large population studies, though the ability of these studies to accurately detect indels may be limited. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 290893). Heterozygous loss of function of the CEL gene is not an established disease mechanism in Maturity-Onset Diabetes of the Young. However, functional studies with another frameshift variant in the same repetitive region suggests that disruption of the repetitive region affects protein secretion and stability, which supports pathogenicity for frameshift variants in this region (PMID: 16369531). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2, PM1 (Richards 2015).	NA	NA	NA
11-2182066-G-A	MODY Extended	LOF	INS	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
11-2181040-G-A	MODY Extended	LOF	INS	NA	NA	NA	NA	likely_not_lof	low pext	NA	6	NA	NA	NA	chr11-2159810-G-A
11-17408574-T-TA	MODY Extended	ClinVar	KCNJ11	555247	546170	27-Nov-17	Likely pathogenic	NA	Reassessed because of possible phenotype mismatch	1	NA	Phenotype of available literature doesn't fit	NA	NA	NA
11-17408737-C-T	MODY Extended	ClinVar	KCNJ11	8683	23722	11-Dec-17	Likely pathogenic	NA	Reassessed because of high allele count	2	NA	Phenotype of available literature doesn't fit	NA	NA	NA
11-17408758-G-A	MODY Extended	ClinVar	KCNJ11	211230	207832	18-Aug-17	NA	NA	Phenotype of available literature doesn't fit, Reassessed because of high allele count	6	1	Phenotype of available literature doesn't fit	NA	NA	chr11-17387211-G-A
11-17408795-C-T	MODY Extended	ClinVar	KCNJ11	8686	23725	31-Oct-18	NA	NA	Phenotype not being assessed for project	1	NA	NA	NA	NA	NA
11-17417461-C-T	Neonatal Diabetes	ClinVar	ABCC8	585346	577178	28-Sep-17	NA	likely pathogenic		1	NA	The p.Arg1379His (sometimes called p.Arg1380His) variant in ABCC8 has been reported in 12 individuals with Monogenic Diabetes and segregated with disease in 5 affected relatives from 2 families (PMID: 22210575, 23093687, 27271189, 21989597, 19342262, 17446535, 17389331; DOI: 10.1016/j.clinph.2015.04.103). Data from large population studies is insufficient to assess the frequency of this variant. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 585346). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Three additional variants, each with a different amino acid change at the same position, (p.Arg1379Leu, p.Arg1379Ser, and p.Arg1379Cys), have been reported in association with disease in the literature and ClinVar, supporting that a change at this position may not be tolerated (PMID: 18025464; Variation ID: 9105, 35614, 35615). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM5, PP1_Moderate, PP3, PS4_moderate (Richards 2015).	Pathogenic	PP1_Moderate, PP3, PS4 (29207974(1), 17389331(1), 31110826(1), 27271189(1), 26438614(1), 22210575(1), 23093687(1 family, two pts),17446535(1)), PM2 (absent in gnomAD, failed QC), PM5(R1379L: Likely path: PP3, PM1, PM2, PS3_mod(18025464 enhanced ATPase activity at NBD2), ?PS4_mod(18025408 (2)), even Path already with PP1_sup. 	NA
11-17417462-G-T	Neonatal Diabetes	ClinVar	ABCC8	35614	44279	9-May-18	NA	vus		2	NA	The p.Arg1379Ser (sometimes called p.Arg1380Ser) variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes (PMID: 25555642), and has been identified in 0.009857% (3/30434) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137852673). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and as a likely pathogenic variant in ClinVar (Variation ID: 35614). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Three additional variants, each with a different amino acid change at the same position, (p.Arg1379Leu, p.Arg1379His, and p.Arg1379Cys), have been reported in association with disease in ClinVar or curated as a likely pathogenic variant or variant of uncertain significance by our study, supporting that a change at this position may not be tolerated (Variation ID: 35615). In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM5, PM2_Supporting, PP3 (Richards 2015).	NA	NA	NA
11-17426099-C-T	Neonatal Diabetes	ClinVar	ABCC8	35609	44274	1-Jan-17	NA	vus	Uncertain significance - insufficient evidence: The p.Val1173Met variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 35609), and has been identified in 0.003098% (4/129110) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs141322087). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 35609). Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Val1173Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, BP4 (Richards 2015).	NA	3	Uncertain significance - insufficient evidence: The p.Val1173Met variant in ABCC8 has been reported in 1 individual with Monogenic Diabetes in ClinVar (Variation ID: 35609), and has been identified in 0.003098% (4/129110) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs141322087). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 35609). Computational prediction tools and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the p.Val1173Met variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, BP4 (Richards 2015).	NA	NA	chr11-17404552-C-T
11-17482160-C-T	Neonatal Diabetes	ClinVar	ABCC8	35624	44289	9-Nov-17	NA	vus		1	NA	Uncertain significance - insufficient evidence: The p.Gly296Arg variant in ABCC8 has been reported in 1 Chinese and 1 Pakistan individuals, in the heterozygous or compound heterozygous state, with Monogenic Diabetes (PMID: 22562119, 26839896), and has been identified in 0.004013% (1/24920) of African chromosomes, 0.003267% (1/30610) of South Asian chromosomes, and 0.001555% (2/128636) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs148529020). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported as a VUS and a likely pathogenic variant in ClinVar (Variation ID: 35624). In vitro functional studies provide some evidence that the p.Gly296Arg variant may slightly increase protein activity (PMID: 22562119). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. This variant is located in the L0 domain, which has been associated with changes in the K-ATP channel of the protein and diabetes (PMID: 22562119). In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3, PS3_Supporting, PM1_Supporting (Richards 2015).	NA	NA	NA
11-17434263-G-A	Neonatal Diabetes	ClinVar	ABCC8	188915	186816	31-Oct-18	NA	NA	Variant assocaited only with Hyperinsulemic hyperglycemia in the literature	12	1	Variant assocaited only with Hyperinsulemic hyperglycemia in the literature	NA	NA	chr11-17412716-G-A
11-17409079-G-A	Neonatal Diabetes	ClinVar	ABCC8,KCNJ11	551187	546193	21-Mar-17	NA	NA	Variant assocaited only with CHI in the literature	NA	1	Variant assocaited only with CHI in the literature	NA	NA	chr11-17387532-G-A
17-36093806-G-A	Neonatal Diabetes	LOF	HNF1B	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
17-36070609-C-T	Neonatal Diabetes	ClinVar	HNF1B	379811	376001	17-Apr-17	NA	vus	Uncertain Significance - Insufficient Evidence: PP1, PM2; also VUS by high confidence lab (GeneDx and EGL) after Jan 2017	19	NA	Uncertain Significance - Insufficient Evidence: PP1, PM2; also VUS by high confidence lab (GeneDx and EGL) after Jan 2017	NA	NA	NA
17-36091625-G-A	Neonatal Diabetes	ClinVar	HNF1B	36837	45498	18-Aug-11	NA	vus	Uncertain significance - insufficient evidence: The p.His336Tyr variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 377055), and has been identified in 0.02611% (9/34468) of Latino chromosomes and 0.0008848% (1/113020) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs138986885). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36837). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.His336Tyr variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	3	5	Uncertain significance - insufficient evidence: The p.His336Tyr variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 377055), and has been identified in 0.02611% (9/34468) of Latino chromosomes and 0.0008848% (1/113020) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs138986885). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36837). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.His336Tyr variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	chr17-37731634-G-A
17-36091682-C-A	Neonatal Diabetes	ClinVar	HNF1B	36854	45515	18-Aug-11	NA	vus		3	NA	Uncertain significance - insufficient evidence: The p.Ala317Ser variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 36854), and has been identified in 0.008674% (3/34588) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922492). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36854). In summary, the clinical significance of the p.Ala317Ser variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	NA
17-36099458-C-T	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	vus		2	NA	Uncertain significance - insufficient evidence: PP3. revel = 0.707 and well conserved, no effect on splicing	NA	NA	NA
17-36099641-A-C	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	vus		1	NA	Uncertain significance - conflicting evidence: PM2, BP7, BP4. 0.002% (2/102988) of European (non-Finnish) chromosomes. One individual is from study cohort. no effect on splicing and nucleotide is not well conserved. no effect on splicing.	NA	NA	NA
17-36104674-C-G	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	vus		1	1	Uncertain significance - conflicting evidence: BA1, PP3. 0.04% (13/30610) of South Asian chromosomes. One of these individuals is from the study cohort. revel = 0.931 and well conserved	NA	NA	chr17-37744683-C-G
17-36104736-G-A	Neonatal Diabetes	ClinVar	HNF1B	36840	45501	18-Aug-11	NA	vus		6	NA	Uncertain significance - insufficient evidence: The p.Pro47Leu variant in HNF1B has been reported in at least 1 individual with Renal Cysts and Diabetes Syndrome in ClinVar (Variation ID: 36840), and has been identified in 0.02024% (7/34580) of Latino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922483). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency. Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 36840). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Pro47Leu variant is uncertain. ACMG/AMP Criteria applied: PM2_Supporting, PP3 (Richards 2015).	NA	NA	NA
17-36104769-G-A	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	vus		18	1	Uncertain significance - conflicting evidence: BA1, PS3_supporting. 0.2% (36/19922) of East Asian chromosomes. Twenty of these individuals are from study cohort. potential GOF mechanism (PMID: 11845238)	NA	NA	chr17-37744778-G-A
17-36104776-G-A	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	vus		5	1	Uncertain significance - conflicting evidence: PM2, BP7, BP4. 0.03% (8/30614, 1 HOM) of South Asian chromosomes. All of these individuals are from study cohort. no effect on splicing and nucleotide is not well conserved. no effect on splicing and nucleotide is not well conserved	NA	NA	chr17-37744785-G-A
17-36093697-T-A	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	benign		2	NA	BA1. 0.03% (6/19950) of East Asian chromosomes. Three of these are from study cohort.	NA	NA	NA
17-36093699-A-G	Neonatal Diabetes	Review	HNF1B	NA	NA	NA	NA	benign		NA	2	BA1. 0.01% (18/129182) of European (non-Finnish) chromosomes and 0.01% (1/10370) of Ashkenazi Jewish chromosomes. One of these individuals is from study cohort.	NA	NA	chr17-37733706-A-G
17-36093738-T-A	Neonatal Diabetes	LOF	HNF1B	NA	NA	NA	NA	likely_not_lof	perfectly viable alternative splice sites nearby, used in other transcripts, Transcript error - minority of transcripts and not expressed	1	NA	NA	NA	NA	NA
17-36065024-G-A	Neonatal Diabetes	LOF	HNF1B	NA	NA	NA	NA	not_lof	pext 0 PHYLOCSF_UNLIKELY_ORF LoF in the overprinted transcript	NA	5	NA	NA	NA	chr17-37705017-G-A
11-2182066-G-A	Neonatal Diabetes	LOF	INS	NA	NA	NA	NA	likely_lof		1	NA	NA	NA	NA	NA
11-2181040-G-A	Neonatal Diabetes	LOF	INS	NA	NA	NA	NA	likely_not_lof	low pext	NA	6	NA	NA	NA	chr11-2159810-G-A
11-17408574-T-TA	Neonatal Diabetes	ClinVar	KCNJ11	555247	546170	27-Nov-17	Likely pathogenic	NA	Reassessed because of possible phenotype mismatch	1	NA	Phenotype of available literature doesn't fit	NA	NA	NA
11-17408737-C-T	Neonatal Diabetes	ClinVar	KCNJ11	8683	23722	11-Dec-17	Likely pathogenic	NA	Reassessed because of high allele count	2	NA	Phenotype of available literature doesn't fit	NA	NA	NA
11-17408758-G-A	Neonatal Diabetes	ClinVar	KCNJ11	211230	207832	18-Aug-17	NA	NA	Phenotype of available literature doesn't fit, Reassessed because of high allele count	6	1	Phenotype of available literature doesn't fit	NA	NA	chr11-17387211-G-A
11-17408795-C-T	Neonatal Diabetes	ClinVar	KCNJ11	8686	23725	31-Oct-18	NA	NA	Phenotype not being assessed for project	1	NA	NA	NA	NA	NA
18-58038771-C-T	Obesity	ClinVar	MC4R	14329	29368	10-Dec-15	NA	pathogenic		NA	4	NA	NA	NA	chr18-60371538-C-T
18-58039478-G-T	Obesity	ClinVar	MC4R	14318	29357	14-Aug-18	Pathogenic	pathogenic		6	3	NA	NA	NA	chr18-60372245-G-T
18-58038746-G-GCA	Obesity	ClinVar	MC4R	36487	45149	18-Aug-11	NA	likely pathogenic		NA	3	NA	NA	NA	chr18-60371513-G-GCA
18-58038831-ATC-A	Obesity	ClinVar	MC4R	435828	430075	29-Jul-16	NA	likely pathogenic		NA	2	NA	NA	NA	chr18-60371598-ATC-A
18-58038834-A-T	Obesity	ClinVar	MC4R	549551	540034	10-Mar-17	NA	likely pathogenic		1	1	NA	NA	NA	chr18-60371601-A-T
18-58039089-C-T	Obesity	ClinVar	MC4R	327713	347739	14-Jun-16	NA	likely pathogenic		1	3	NA	NA	NA	chr18-60371856-C-T
18-58039134-G-A	Obesity	ClinVar	MC4R	435829	430076	18-Oct-16	NA	likely pathogenic		5	NA	NA	NA	NA	NA
18-58039203-G-A	Obesity	ClinVar	MC4R	14336	29375	25-May-17	NA	likely pathogenic	Conflicting evidence	9	5	NA	NA	NA	chr18-60371970-G-A
18-58039402-C-T	Obesity	ClinVar	MC4R	435831	430078	30-Aug-16	NA	likely pathogenic	PM2 (Absent in population databases) upgraded in strength to Strong, PS4 (Prevalence in affecteds statistically increased over controls) upgraded in strength to Very Strong	1	4	NA	NA	NA	chr18-60372169-C-T
18-58038699-G-T	Obesity	LOF	MC4R	NA	NA	NA	NA	lof	single exon gene	NA	1	NA	NA	NA	chr18-60371466-G-T
18-58038746-G-GCA	Obesity	LOF	MC4R	36487	45149	18-Aug-11	NA	lof	single exon gene	NA	3	NA	NA	NA	chr18-60371513-G-GCA
18-58038746-GCA-G	Obesity	LOF	MC4R	NA	NA	NA	NA	lof		1	NA	NA	NA	NA	NA
18-58038753-CAA-C	Obesity	LOF	MC4R	NA	NA	NA	NA	lof	single exon gene	NA	1	NA	NA	NA	chr18-60371520-CAA-C
18-58038810-C-T	Obesity	LOF	MC4R	NA	NA	NA	NA	lof	single exon gene	NA	1	NA	NA	NA	chr18-60371577-C-T
18-58038831-ATC-A	Obesity	LOF	MC4R	435828	430075	29-Jul-16	NA	lof	single exon gene	NA	2	NA	NA	NA	chr18-60371598-ATC-A
18-58038892-CG-C	Obesity	LOF	MC4R	NA	NA	NA	NA	lof		2	NA	NA	NA	NA	NA
18-58039238-CTG-C	Obesity	LOF	MC4R	NA	NA	NA	NA	lof	single exon gene	NA	2	NA	NA	NA	chr18-60372005-CTG-C
18-58039478-G-T	Obesity	LOF	MC4R	14318	29357	14-Aug-18	Pathogenic	lof	single exon gene	6	3	NA	NA	NA	chr18-60372245-G-T
18-58039527-CT-C	Obesity	LOF	MC4R	NA	NA	NA	NA	lof	single exon gene	NA	1	NA	NA	NA	chr18-60372294-CT-C
18-58038752-A-T	Obesity	LOF	MC4R	NA	NA	NA	NA	likely_lof		3	NA	NA	NA	NA	NA
18-58038687-G-T	Obesity	ClinVar	MC4R	36488	45150	18-Aug-11	NA	vus	Conflicting evidence	1	1	NA	NA	NA	chr18-60371454-G-T
18-58038777-A-T	Obesity	ClinVar	MC4R	36486	45148	14-Mar-17	NA	vus		200	NA	NA	NA	NA	NA
18-58038826-C-T	Obesity	ClinVar	MC4R	492862	485791	4-Mar-14	NA	vus		7	8	NA	NA	NA	chr18-60371593-C-T
18-58039060-C-T	Obesity	ClinVar	MC4R	14330	29369	16-Mar-11	NA	vus	Conflicting evidence	35	7	NA	NA	NA	chr18-60371827-C-T
18-58039422-A-G	Obesity	ClinVar	MC4R	492861	485792	4-May-17	NA	vus		1	NA	NA	NA	NA	NA
